



Anais da Academia Brasileira de Ciências

ISSN: 0001-3765

aabc@abc.org.br

Academia Brasileira de Ciências

Brasil

AVELLAR, MARIA CHRISTINA W.; LÁZARI, MARIA FATIMA M.; PORTO, CATARINA S.  
Expression and function of G-protein-coupled receptors in the male reproductive tract  
Anais da Academia Brasileira de Ciências, vol. 81, núm. 3, septiembre, 2009, pp. 321-344  
Academia Brasileira de Ciências  
Rio de Janeiro, Brasil

Available in: <http://www.redalyc.org/articulo.oa?id=32713479002>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org

redalyc.org

Scientific Information System

Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal

Non-profit academic project, developed under the open access initiative



Anais da Academia Brasileira de Ciências (2009) 81(3): 321-344  
(Annals of the Brazilian Academy of Sciences)  
ISSN 0001-3765  
www.scielo.br/aabc

## Expression and function of G-protein-coupled receptors in the male reproductive tract

MARIA CHRISTINA W. AVELLAR, MARIA FATIMA M. LÁZARI and CATARINA S. PORTO

Setor de Endocrinologia Experimental, Departamento de Farmacologia, Universidade Federal de São Paulo  
Escola Paulista de Medicina, Rua Três de Maio, 100, 4º andar, Vila Clementino, 04044-020 São Paulo, SP, Brasil

*Manuscript received on July 6, 2008; accepted for publication on August 14, 2008;  
presented by LUIZ R. TRAVASSOS*

### ABSTRACT

This review focuses on the expression and function of muscarinic acetylcholine receptors (mAChRs),  $\alpha_1$ -adrenoceptors and relaxin receptors in the male reproductive tract. The localization and differential expression of mAChR and  $\alpha_1$ -adrenoceptor subtypes in specific compartments of the efferent ductules, epididymis, vas deferens, seminal vesicle and prostate of various species indicate a role for these receptors in the modulation of luminal fluid composition and smooth muscle contraction, including effects on male fertility. Furthermore, the activation of mAChRs induces transactivation of the epidermal growth factor receptor (EGFR) and the Sertoli cell proliferation. The relaxin receptors are present in the testis, RXFP1 in elongated spermatids and Sertoli cells from rat, and RXFP2 in Leydig and germ cells from mouse and human, suggesting a role for these receptors in the spermatogenic process. The localization of both receptors in the apical portion of epithelial cells and smooth muscle layers of the vas deferens suggests an involvement of these receptors in the contraction and regulation of secretion.

**Key words:** muscarinic acetylcholine receptors,  $\alpha_1$ -adrenoceptors, relaxin receptors, male reproductive tract.

### INTRODUCTION

G-protein-coupled receptors (GPCRs) play different roles in autocrine and neuronal systems and are important in the physiology and pathophysiology of various organs. The activation of these receptors may affect cell proliferation, differentiation, growth and other functions in the male reproductive tract organs. This review focuses on the expression and function of muscarinic acetylcholine receptors (mAChRs),  $\alpha_1$ -adrenoceptors and relaxin receptors in the male reproductive tract. Firstly, the differential expression of mAChR subtypes ( $M_1$ ,  $M_2$ ,  $M_3$ ,  $M_4$  and  $M_5$ ) in Sertoli cells, efferent ductules, epididymis, seminal vesicle and their pharmaco-

logical characteristics, intracellular signaling and possible interaction with growth factors are presented. Secondly, aspects of the genomic organization, structure and tissue distribution in the male reproductive tract and pharmacological characteristics and function of the different  $\alpha_1$ -adrenoceptors subtypes ( $\alpha_{1A}$ -,  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenoceptors) are reviewed. Lastly, the function and contribution in the male reproductive organs of the recently discovered relaxin receptors are discussed.

### MUSCARINIC ACETYLCHOLINE RECEPTOR SUBTYPES, EXPRESSION AND CELLULAR SIGNALING MECHANISMS IN THE MALE REPRODUCTIVE TRACT

The cellular actions of acetylcholine (ACh) and



me et al. 1990, Caulfield and Birdsall 1998, Wess 2004, Eglen 2006). mAChRs are class I heptahelical G-protein-coupled receptors (GPCRs) and comprise five distinct subtypes ( $M_1$  to  $M_5$ ) encoded by different intronless genes (Kubo et al. 1986). The similarity in ligand-binding sites across the five subtypes explains why the development of subtype-selective ligands has been difficult (Hulme et al. 1990). In addition to agonist-binding sites, mAChRs possess allosteric sites that bind modulators of receptor activation. These allosteric sites differ from the agonist-binding site, and they are receptor-subtype specific, a characteristic especially favorable for the design of subtype-selective modulators (Birdsall and Lazareno 2005).

The coupling of mAChRs to their cellular effector systems is mediated via heterotrimeric guanine nucleotide-binding proteins (G-proteins) (for review see Lanzafame et al. 2003).  $M_1$ ,  $M_3$  and  $M_5$  mAChRs preferentially couple with  $G_{q/11}$ , mobilize phosphoinositides to generate inositol 1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG) via activation of phosphoinositide-specific phospholipase  $C\beta$  (PLC $\beta$ ), leading to an increase in intracellular  $Ca^{2+}$  and protein kinase C (PKC) activity.  $M_2$  and  $M_4$  mAChRs preferentially couple with  $G_{i/o}$  and inhibit elevated adenylylcyclase activity.  $M_2$  mAChRs, via  $G\beta\gamma$ , can also activate PLC $\beta$ . Furthermore, mAChRs have also been shown to regulate other signaling pathways. Hence, both  $G\alpha_{q/11}$ - and  $G\alpha_{i/o}$ -coupled with mAChRs may exert effects through activation of small GTPases, such as Rho and Ras, and downstream effectors, such as phosphoinositide-3 kinases (PI3 kinases), non-receptor tyrosine kinases, and mitogen-activated protein kinases (MAP kinases) (for review see Lanzafame et al. 2003, van Koppen and Kaiser 2003). The latter signaling pathway seems to play a major role in the autocrine functions of mAChRs in terms of the control of cell growth or proliferation, secretion by epithelial cells, and apoptosis (for review see Eglen 2006).

The importance of mAChRs for fertility has been revealed by the demonstration that mAChR antagonists impair fertility in male rats (Ban et al. 2002, Sato et al. 2005), but the underlying mechanisms that cause

the male reproductive tract is essential to understand the role of the cholinergic nervous system in male fertility.

In an attempt to clarify the pathophysiology of idiopathic male infertility and to develop new methods for male contraception, researchers have focused on local regulators of intratesticular events (Huleihel and Lunenfeld 2004, Walker and Cheng 2005, Yan et al. 2007) and Sertoli cells play an important role in this process (Skinner 2005). Studies from our laboratory have shown the presence of  $M_1$  to  $M_5$  mAChRs (mRNA and protein) in primary culture of Sertoli cells from 15-day and 30-day old rats (Borges et al. 2001, Lucas et al. 2008). mAChRs have been localized in plasma membrane, cytoplasmic organelles, perinuclear region and nuclei in cultured Sertoli cells from 15-day old rats by using immunofluorescence studies and confocal laser scanning microscopy.  $M_1$ ,  $M_3$  and  $M_5$  mAChR subtypes are mainly localized in the cell nuclei, with a weak to moderate staining visible in the plasma membrane and perinuclear region of Sertoli cells. On the other hand,  $M_2$  and  $M_4$  mAChR subtypes are predominantly localized in the plasma membrane, with some staining in the perinuclear region (Lucas et al. 2008). Although the functional significance of mAChRs in the plasma membrane is well established, their presence in subcellular regions has been observed in several cell types (Bernard et al. 1999, 2003, Salamanca et al. 2005). The number of receptors at the plasma membrane is frequently regulated to modulate cell responses upon stimulation. Therefore, the intracellular pool of mAChRs may represent both newly synthesized and recycled stores of receptors in amounts that vary with the balance between the rate of synthesis and the shedding and desensitization processes. The neurochemical environment may contribute to the control of the abundance and availability of cell surface receptors and, consequently, to the control of neuronal sensitivity to neurotransmitters or mAChR agonists, by regulating their delivery from the endoplasmic reticulum and Golgi complex (Bernard et al. 1999, 2003).

The presence of mAChRs gives support to the idea that the cholinergic neurotransmission may have a phys-




#### GPCRS IN THE MALE REPRODUCTIVE TRACT

cultured Sertoli cells from immature hamster (Davenport and Heindel 1987) and induces phosphoinositide hydrolysis and time-dependent stimulation of the activator protein-1 DNA-binding activity in cultured Sertoli cells from 30-day old rats (Borges et al. 2001). The activation of mAChRs also rapidly stimulates [methyl- $^3\text{H}$ ]thymidine incorporation in cultured Sertoli cells obtained from 8-day and 15-day old rats, in a concentration-dependent and time-dependent manner, suggesting an induction of DNA synthesis and/or DNA repair (Lucas et al. 2004). Furthermore, the activation of mAChRs induces transactivation of the epidermal growth factor receptor (EGFR) through  $\beta\gamma$ -subunits of G proteins that promote Src-mediated metalloprotease-dependent cleavage and release of EGFR ligands from the cell surface and binding to EGFR and activation of extracellular signal-regulated kinases (Erk)1/2 in Sertoli cells from 15-day old rats. PLC $\beta$  and intracellular  $\text{Ca}^{2+}$  mobilization, but not PKC, are involved in the Erk1/2 phosphorylation induced by mAChRs in Sertoli cells (Lucas et al. 2008). The transactivation of EGFR by the agonist-mAChR complex is also involved in the Sertoli cell proliferation (Lucas et al. 2008). The characterization of the signaling pathways regulated by the agonist-mAChR complex in Sertoli cells is an important step to understand how this complex may support spermatogenesis. It is important that future studies focus on components of the MAP kinase pathway, such as transcription factors, regulatory kinases and phosphatases, and the involvement of other signaling pathways that could be mediated by mAChRs, such as activation of PI3 kinase and phospholipase A<sub>2</sub> (PLA<sub>2</sub>), as they may represent additional mechanisms for the regulation of protein secretion and cell junction dynamics in the testis.

In the rat epididymis, studies from our laboratory have shown the presence of mRNA for M<sub>1</sub>, M<sub>2</sub> and M<sub>3</sub> mAChRs in the caput and cauda region (Maróstica et al. 2001, 2005). The levels of mRNA for M<sub>2</sub> subtype are higher in the cauda than in the caput of the epididymis. Low levels of M<sub>1</sub> mRNA are present in the caput and cauda of the epididymis, and low levels of M<sub>3</sub> mRNA are found in the caput region (Maróstica et al. 2005).

Immunolocalization of mAChR subtypes in different ductules and epididymis has indicated a variable degree of immunostaining for each mAChR subtype, with a cell-type and tissue-specific pattern (Siu et al. 2006). M<sub>1</sub> mAChR is detected in the epithelium of the efferent ductules, while M<sub>2</sub> and M<sub>3</sub> mAChRs are observed in the apical region of the ciliated cells of the efferent ductules. Apical and narrow cells of the initial segment of the epididymis show a distinct staining for M<sub>1</sub> subtype, whereas supranuclear localization is noted in the principal cells of the caput of the epididymis. In addition, staining for M<sub>1</sub> and M<sub>2</sub> mAChRs is visible in the apical membrane of some epithelial cells of the cauda region of the epididymis (Siu et al. 2006). These findings support the relationship between mAChRs activation and secretory processes. In fact, the activation of mAChRs stimulates chloride secretion in cultured rat epididymal epithelial cells (Du et al. 2006), and increases [ $^{35}\text{S}$ ]-Methionine incorporation in proteins secreted by rat efferent ductules and in secreted and tissular proteins of the caput region of the epididymis. These effects were abolished by atropine, a nonselective mAChR antagonist (E.R. Siu et al. unpublished data). Immunoreactivity for M<sub>3</sub> mAChR is detected in the peritubular smooth muscle of the efferent ductules and along the different epididymal regions, with a strong reaction in the proximal and distal regions, suggesting that this receptor subtype may play a role in smooth muscle contraction (Siu et al. 2006). The hexahydro-sila-difenidol (HHSiD), a M<sub>3</sub>/M<sub>1</sub> selective mAChR antagonist, is able to abolish contractions induced by carbachol, a stable analog of ACh, indicating the involvement of M<sub>3</sub> mAChRs in the epididymal smooth muscle contraction (Siu et al. 2006). Cell-specific expression of the mAChR subtypes in the efferent ductules and epididymis suggests the role of these receptors in the regulation of smooth muscle contraction and the composition of the luminal fluid, which is essential for post-testicular maturation of spermatozoa.

In the dog vas deferens, binding studies have shown the presence of mAChRs. The prostatic region expresses a greater amount of mAChRs than the intermediate and epididymal regions (Kondo et al. 1994). mAChRs



potentiates  $P_{2X}$  receptor-mediated contractions, but not adrenoceptor-mediated contractions (Iram and Hoyle 2005). In rabbit vas deferens, prejunctional  $M_1$  mAChRs inhibit the release of endogenous noradrenaline (Grimm et al. 1994) and the contractile response of vas deferens (Shannon et al. 1993). The presence of mRNA or protein for  $M_1$ ,  $M_2$  and  $M_3$  mAChRs has also been shown in rat vas deferens (Miranda et al. 1994, 1995), and  $M_1$  and  $M_2$  mAChRs are involved in the contraction of the epididymal region of rat vas deferens (Doggrell 1986). The cell- and region-specific expression of mAChR subtypes in vas deferens and the role of each subtype in different species remain to be explored.

The presence of mRNA for the five mAChRs has been shown in the rat seminal vesicle (Hamamura et al. 2006).  $M_3$  mAChR is predominantly involved in the contraction of the seminal vesicle in guinea-pigs (Eglen et al. 1992) and rats (Hamamura et al. 2006). Immunohistochemical studies revealed the presence of  $M_2$  and  $M_3$  mAChRs in the smooth muscle layers of the rat seminal vesicle (Hamamura et al. 2006).  $M_2$  and  $M_3$  mAChRs may also be involved in protein secretion since they are present in epithelial cells of the rat seminal vesicle (Hamamura et al. 2006). Other evidence that supports this suggestion is that mAChR agonists stimulate protein secretion in cultured epithelial cells of the rat seminal vesicle (Kinghorn et al. 1987), alkaline phosphatase secretion and phospholipid synthesis in the guinea-pig seminal vesicle (Lockwood and Williams-Ashman 1971), and fructose release from epithelial cells of guinea-pig seminal vesicle via nitric oxide production (Ehrén et al. 1997). Apart from the effects on protein secretion, mAChRs are also involved in mitogenic effects in cultured epithelial cells from the rat seminal vesicle (Kinghorn et al. 1987). Recent studies from our laboratory have shown that the mechanism by which agonist-mAChR acts in seminal vesicle involves the transactivation of the EGFR through  $G\beta\gamma$ -subunits proteins that promote Src-mediated metalloprotease-dependent cleavage and release of EGFR ligands from the cell surface and binding to EGFR and Erk1/2 activation. Furthermore, PLC intracellular  $Ca^{2+}$  mobilization and

et al., unpublished data). Further studies are necessary to understand the role of the agonist-mAChR-Erk1/2 in the proliferation, differentiation and secretion in the seminal vesicle and, consequently, the impact of the cholinergic nervous system to male fertility.

The presence of  $M_2$  mAChR in the rat prostate has been shown by immunoprecipitation studies (Ruggieri et al. 1995). On the other hand, binding studies with selective antagonists suggested the presence of  $M_3$  mAChRs (Lau and Pennefather 1998), and immunostaining confirmed the presence of  $M_3$  mAChR in the outer muscle layer surrounding the prostatic acini (Nadelhaft 2003). In fact, mAChR agonist-induced contractions of the ventral lobe of the rat prostate seem to be mediated by  $M_3$  mAChR (Lau and Pennefather 1998, Ventura et al. 2002). The expression of mAChR subtypes varies among the different lobes of the rat prostate; immunohistochemistry combined with RT-PCR analysis suggests that  $M_3$  mAChRs are predominantly expressed in the ventral lobe and  $M_2$  mAChRs in the dorsolateral lobe (Pontari et al. 1998). The activation of mAChRs in rat prostate gland induces glandular secretion (Wang et al. 1991) and increases  $Ca^{2+}$  with concomitant activation of  $K^+$  and  $Cl^-$  channels, which are essential for fluid secretion (Kim et al. 2005).

$M_2$  mAChR mRNA (Obara et al. 2000) and protein (Yazawa et al. 1994) are detected in cultured prostate smooth muscle cells from human patients with benign prostatic hypertrophy. Additionally,  $M_1$  mAChRs are present on glandular epithelial cells from these patients (Ruggieri et al. 1995) and  $M_3$  mAChR is present in the LNCaP prostatic cancer cell line (Rayford et al. 1997). Other studies in prostate cell lines have revealed controversial findings. LNCaP cells, as well as DU145 cells, express approximately equal amounts of  $M_1$  and  $M_3$  mAChRs, whereas PC3 cells express only  $M_3$  mAChRs (Luthin et al. 1997), and mAChR agonist increases phosphatidylinositol turnover in PC3, but not in DU145 or LNCaP cell lines.

A high expression of  $M_3$  mAChRs has been correlated with differentiation of the human prostatic epithelium (Blanco and Robinson 2004). Normal prostate



#### GPCRS IN THE MALE REPRODUCTIVE TRACT

served in Jun N-terminal kinase activity (Ruggieri et al. 1995, Luthin et al. 1997). On the other hand, mAChR agonist induces growth of prostate epithelial cells and an increase in Erk activity in several prostate cancer cell lines (Rayford et al. 1997, Luthin et al. 1997), while in PC3 prostate carcinoma cells, mAChR activation induces transactivation of EGFR (Prenzel et al. 1999). Moreover, several studies suggest a direct or indirect role for the Erk1/2 signaling pathway in the development of prostate cancer (Papatsoris et al. 2007), but reports of Erk1/2 activation in prostate cancer have been controversial. Further characterization is necessary to understand the role of the agonist-mAChR complex and the intracellular signaling pathways involved in secretion, proliferation and differentiation in the prostate.

Multiple factors may be involved in the regulation of mAChRs. Briefly, studies have pointed out the importance of a physiological balance between androgen and testicular factors in the regulation of mAChRs in the rat epididymis (Maróstica et al. 2005). Moreover, androgen also modulates mAChRs present in the rat vas deferens (Longhurst and Brotcke 1989) and prostate (Shapiro et al. 1985).

#### $\alpha_1$ -ADRENOCEPTORS: SUBTYPES AND EXPRESSION IN THE MALE REPRODUCTIVE TRACT

The natural adrenergic amines, adrenaline and noradrenaline, are among the most important regulators of physiological functions and biochemical processes in the organism, through their release by adrenal medulla and related chromaffin structures and the sympathetic nervous system (for review see Docherty 2002, Jackson and Cunnane 2001, Eisenhofer 2001). With adrenergic nerve stimulation, noradrenaline is released from the nerve terminal. The action of this neurotransmitter can be mediated on the target cell by three subfamilies of G-protein-coupled receptors ( $\alpha_1$ ,  $\alpha_2$  and  $\beta$ -adrenoceptors), each of them comprising different receptor subtypes which are products of separate genes:  $\alpha_1$  ( $\alpha_{1A}$ -,  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenoceptors);  $\alpha_2$  ( $\alpha_{2A}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptors) and  $\beta$  ( $\beta_1$ -,  $\beta_2$ - and  $\beta_3$ -adrenoceptors). They play important roles in the regulation of diverse physi-

views see Langer 1999, Ruffolo and Hieble 1999, and Minneman 1999, Brodde and Leineweber 2000). In this review, aspects of the genomic organization, structure, tissue distribution in the male reproductive tract and function of  $\alpha_1$ -adrenoceptors are presented.

$\alpha_1$ -adrenoceptor subtypes ( $\alpha_{1A}$ -,  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenoceptor) are encoded by three separate genes noted *ADRA1A*, *ADRA1B* and *ADRA1D* as single protein products (Morrow and Creese 1986, Schmitz et al. 1990, Ramarao et al. 1992, Yang-Feng et al. 1994, Hieble et al. 1995, Piascik et al. 1995, De Luca 1998). All  $\alpha_1$ -adrenoceptor subtypes contain:

- 1) a common overall structure with seven hydrophobic transmembrane (TM1-TM7) helices interconnected by hydrophilic sections composed of two intracellular and three extracellular loops;
- 2) an extracellular N-termini which contains consensus sites for N-linked glycosylation (Sawutsky et al. 1987);
- 3) an intracellular C-termini which contains consensus sites for phosphorylation by protein kinase C (Leeb-Lundberg et al. 1985, Lefkowitz 1999, Lefkowitz et al. 1998, Vázquez-Prado et al. 1999) and interaction with regulatory proteins (Hieble et al. 2001, Pupo and Minneman 2003, Diviac et al. 2003); and
- 4) second and third intracellular loops that are involved in the coupling with heterotrimeric G-proteins (Hieble et al. 1995, Lefkowitz and Hieble 1988, Graham et al. 1996).

Functional studies and computational molecular modeling also indicate amino acids located mainly on membrane domains TM3, TM5 and TM6 with important role in the binding of the endogenous catecholamines to  $\alpha_1$ -adrenoceptors (Piascik and Perez 2001, Portillo et al. 1996, Hwa and Perez 1996, Chen et al. 1999, Wang et al. 2000, Hwa et al. 1995, 1996, Pedretti et al. 2000).

All three  $\alpha_1$ -adrenoceptor genes present a general structure of at least two exons separated by a large intron ranging from 7.2–93 kbp in different



domain TM6 of the receptor, while the second exon encodes the third extracellular loop, transmembrane domain TM7 and all (or most) of the C-terminal region (Ramarao et al. 1992, Esbenshade et al. 1995). Additional exons are known to be present in the *ADRA1A* gene in human (Hirasawa et al. 1995, Chang et al. 1998, Cogé et al. 1999, Patrão et al. 2008), rabbit (Suzuki et al. 2000), guinea-pig (González-Espinosa et al. 2001) and rhesus monkey (Patrão et al. 2008), whose alternative use leads to several transcript variants by splicing mechanisms. In humans, at least eleven different *ADRA1A* splice variants have been reported (Hawrylyshyn et al. 2004). A summary of the nomenclature of the genes, transcripts and their corresponding isoforms for all these splicing variants can be found in Patrão et al. (2008). Four of these variants, differing in length and sequence of the C-terminal region, are functional proteins with pharmacological profile and ability to mediate effects induced by norepinephrine similar to the classical  $\alpha_{1A}$ -adrenoceptor (wild type, *ADRA1A\_i1*) (Hirasawa et al. 1995, Chang et al. 1998, Cogé et al. 1999, Hawrylyshyn et al. 2004). They present, however, differences in G-protein coupling specificity and down-regulation mechanisms are suggested among these splice variants (Hirasawa et al. 1995, Chang et al. 1998, Price et al. 2002). The other seven human splice variants, differing in length and sequence in the C-terminal region, code for non-functional truncated isoforms that lack TM7 and, for this reason, are incapable of ligand binding and activating signal transduction (Chang et al. 1998, Cogé et al. 1999, Hawrylyshyn et al. 2004). Differences in the relative abundance, cellular localization and possible functions for these *ADRA1A* gene splice variants have been suggested (Hirasawa et al. 1995, Cogé et al. 1999, Schwinn and Kwatra 1998, Ramsay et al. 2004, Patrão et al. 2008). Functional and truncated *ADRA1A* splice variants are differentially expressed in different tissues of the male reproductive tract of humans and rhesus monkeys (testis, epididymis, prostate and seminal vesicle), raising the question about their relevance in physiological and pathological events in these tissues (Patrão et al.

splices variants in humans and other species, however, remains to be determined.

All three  $\alpha_1$ -adrenoceptor subtypes show similar potencies and intrinsic efficacies to endogenous ligands released from the sympathetic fibers (noradrenaline and adrenaline) and high affinity to the nonspecific  $\alpha_1$ -adrenoceptor antagonist prazosin (Hieble and Ruffolo 1996). A fourth subtype has been proposed based on its lower affinity to prazosin. The receptor subtype, designated  $\alpha_{1L}$ -adrenoceptor, is probably not a distinct receptor but rather a low-affinity state of the  $\alpha_{1A}$ -adrenoceptor (Ford et al. 1997, Daniels et al. 1999) and has been reported to be involved in smooth muscle contraction of human, rabbit and dog lower urinary tract tissues (Muramatsu et al. 1994, Ford et al. 1996, Testa et al. 1996, Fukasawa et al. 1998) with an important role in the treatment of stress urinary incontinence (Bishop 2007). The antagonists 5-methyl urapidil, WB 4101 and niguldipine show higher affinity for  $\alpha_{1A}$ -adrenoceptors, while BMY 7378 recognizes preferentially  $\alpha_{1D}$ -adrenoceptors (Deng et al. 1996, Saussy et al. 1996, Yang et al. 1997). The alkylating agent chloroethylclonidine is an irreversible antagonist that mostly inactivates both  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenoceptors (Laz et al. 1994, Hieble et al. 1995, Xiao and Jeffries 1998).

$\alpha_1$ -adrenoceptors are preferentially coupled with  $G_{q/11}$  protein and activate phospholipase  $C\beta$  to form DAG and  $IP_3$ , inducing consequent increase in cytosolic concentration of  $Ca^{2+}$  and PKC, which in turn phosphorylates several substrates (Zhong and Minneman 1999, Hein and Michel 2007). The relative coupling efficiencies to second messenger formation differs depending on the receptor subtype ( $\alpha_{1A} > \alpha_{1B} > \alpha_{1D}$ ; Theroux et al. 1996, Zhong et al. 2001). There are also evidences that, depending on the cell or tissue which were analyzed,  $\alpha_1$ -adrenoceptors can also couple with different G protein ( $G_i$ ,  $G_s$  and  $G_h$ ; Horie et al. 1995, Hu and Nattel 1995, Chen et al. 1996, Nakaoka et al. 1994, Shinoura et al. 2002) activating different signaling pathways to modulate cellular function (Michelotti et al. 2000, Wier and Morgan 2003) and possibly modulating L-type calcium, sodium and cation channels from



#### GPCRS IN THE MALE REPRODUCTIVE TRACT

The complexity of the events involved in  $\alpha_1$ -adrenoceptor activation is further demonstrated by the fact that several interacting proteins can allow differential signalling, regulation and subcellular localization for each subtype  $\alpha_1$ -adrenoceptors (Hu and Nattel 1995, Chen et al. 1996, Wang et al. 2005, Xu et al. 1999). Also, there are evidences that  $\alpha_{1A}$ -,  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenoceptors are all capable to form homodimers and homotrimers (Vicentic et al. 2002). Oligomerization of  $\alpha_{1B}$ -adrenoceptors seems to be required for proper receptor function, since mutations of putative key hydrophobic residues in transmembrane domain TM1 and transmembrane domain TM4 prevent receptor oligomerization and result in impaired  $\alpha_{1B}$ -adrenoceptor cell-surface expression and signaling (Lopez-Gimenez et al. 2007).  $\alpha_1$ -adrenoceptors are also capable to heterodimerize (Uberti et al. 2003, 2005, Hague et al. 2004a).

The subcellular localization of the  $\alpha_1$ -adrenoceptor subtypes can also confer distinct receptor function, as known to occur with other G-protein-coupled receptors (for review see Gobeil et al. 2006). The presence of intracellular  $\alpha_1$ -adrenoceptors has been described in the literature (Piascik and Perez 2001, Hirasawa et al. 2001, Toews et al. 2003). Studies with recombinant receptor have identified a characteristic distribution of  $\alpha_{1A}$ -adrenoceptors throughout the cytoplasm of the cell, whereas  $\alpha_{1B}$ -adrenoceptors mainly present classic plasma membrane labeling pattern (Hirasawa et al. 1997, Sugawara et al. 2002). Intracellular staining of  $\alpha_{1A}$ -adrenoceptors in epithelial cells of the epididymis, vas deferens and seminal vesicle of rats has been also reported (Queiróz et al. 2008), confirming that this location of the receptor might be important in physiological events. In human prostatic smooth muscle cells, approximately 40% of the  $\alpha_1$ -adrenoceptors were intracellular, particularly concentrated around the nucleus (Mackenzie et al. 2000). Similar results were observed in cultured vascular smooth muscle cells and rat-1 fibroblasts transfected with the  $\alpha_1$ -adrenoceptor subtypes, although significant expression of  $\alpha_{1A}$ -adrenoceptor in these cells was located in the plasma membrane (Hrometz et al. 1999, McCune et al. 2000). Conversely,  $\alpha_{1B}$ -adreno-

et al. 1997, McCune et al. 2000, Chalothorn et al. 2002, Hague et al. 2004b), probably because of the terminal region of the protein that regulates expression of functional receptors in the cell membrane (Hague et al. 2004a, b).  $\alpha_1$ -adrenoceptors can bind competitively to the fluorescent antagonist BODIPY FL-pyrene (Daly et al. 1998, Mackenzie et al. 2000, Sullivan et al. 2002), raising the possibility that these receptors are probably functional and involved in signal transduction. Possible ligands for these intracellular receptors could be catecholamines penetrating the cells either by diffusion/lipophilicity or through transport by transmembrane carriers in postsynaptic cells (Mackenzie et al. 2000, Haag et al. 2004).

Functional, molecular and radioligand binding studies have been extensively used to characterize the distribution and tissue distribution of  $\alpha_1$ -adrenoceptor subtypes in different tissues from different species, including humans (Langer 1999, Zhong and Minneman 1999, Varrault et al. 2000, Deng 2000, Rokosh et al. 1994, Hieble et al. 1994, Price et al. 1994a, b, Rudner et al. 1999, Silva et al. 1999, Errasti et al. 2003, Scarparo et al. 2004). The heterogeneity of  $\alpha_1$ -adrenoceptors is a common feature in tissues of the male reproductive tract of rodents and humans, including testis, prostate (Rokosh et al. 1994, Scofield et al. 1995, Nasu et al. 1996, 1998, Piascik et al. 2008), testis capsule (Jurkiewicz et al. 2006), seminal vesicle (Silva et al. 1999, Mendes et al. 2004, Queiróz et al. 2008) and epididymis (Queiróz et al. 2002, 2008). In all these tissues, a predominance of  $\alpha_{1A}$  mRNA subtype is observed. High abundance of *Adra1d* transcripts is found in rat cauda epididymis (Queiróz et al. 2002), seminal vesicle (Silva et al. 2004, Mendes et al. 2004) and human prostate (Nasu et al. 1998, Moriyama et al. 1996), while vas deferens, epididymis and other genitourinary tissues present abundant *Adra1a* and *Adra1d* mRNAs with relative low levels of *Adra1b* transcripts (Piascik et al. 1997, Cawston et al. 2002). Levels of *Adra1b* and *Adra1d* mRNAs vary during rat brain development, showing that different receptor subtypes may have different ontogenetic patterns of distribution leading to differential tissue





Functional studies also reveal that a predominant population of  $\alpha_{1A}$ -adrenoceptors is involved in the contractile response of smooth muscle from vas deferens, prostate and seminal vesicle (Mallard et al. 1992, Aboud et al. 1993, Yazawa and Honda 1993, Lepor et al. 1994, Teng et al. 1994, Burt et al. 1995, 1998, Pupo 1998, Silva et al. 1999). Interestingly, the presence of  $\alpha_{1A}$ - and  $\alpha_{1B}$ -adrenoceptors is detected in rat vas deferens by radioligand binding studies (Hanft and Gross 1989, Salles and Badia 1991, Vivas et al. 1997), indicating that the correlation of binding and functional assays are not always directly correlated (Zhong and Minneman 1999). However, the contractions of vas deferens from cyproterone acetate-treated rats involves the participation of both  $\alpha_{1A}$ - and  $\alpha_{1B}$ -adrenoceptors, indicating that this antiandrogen induces plasticity in the functional  $\alpha_1$ -adrenoceptor subtypes in the rat vas deferens (Campos et al. 2003). Divergence between receptor detection through functional methods versus molecular biology methods has also been discussed by Forray et al. (1994) and MacKinnon et al. (1994). Participation of  $\alpha_{1A}$ -adrenoceptor in the contractile response of cauda epididymis from mouse (Hib and Caldeyro-Barcia 1974), in spontaneous contractions of rat epididymis regions (Da Silva et al. 1975, Hib 1976, Chaturapanich et al. 2002) and in events related to epithelial function such as electrolyte transport (Leung et al. 1992, Chan et al. 1994) and protein processing (Ricker et al. 1996) have been reported. A predominant population of  $\alpha_{1A}$ -adrenoceptor in rat epididymis has been also confirmed by radioligand binding assays (Queiróz et al. 2002) and immunohistochemistry, which located this receptor subtype in smooth muscle and in subpopulations of epithelial cells from human and rat epididymis (Queiróz et al. 2008) and rhesus monkey (Patrão et al. 2008). The expression of different  $\alpha_1$ -adrenoceptor mRNA subtypes are known to occur along rat epididymis (Queiróz et al. 2002), raising the possibility of possible differential importance of  $\alpha_1$ -adrenoceptor subtypes in different epididymal cells during physiological and pathological events, including effects on male fertility. In fact, studies by Bhathal et al. (1974) and Ratnasooriya and Wadsworth (1990, 1994)

with different  $\alpha_1$ -adrenoceptor antagonists induces a decrease in ejaculatory capacity associated with a reduction in the fertilization ability of the sperm, suggesting a role for the sympathetic nervous system in fertility maintenance via  $\alpha_1$ -adrenoceptors (Ratnasooriya and Wadsworth 1990, 1994).

Although it is known that, in most tissues, mixtures of  $\alpha_1$ -adrenoceptor subtypes (mRNA and protein) are concomitantly expressed, with variable relative expression levels (Zhong and Minneman 1999), quantification and localization of all three  $\alpha_1$ -adrenoceptor subtypes at protein level have been difficult to be determined mainly due to the lack of pharmacological tools with selectivity or specificity, and the high degree of conservation of the  $\alpha_1$ -adrenoceptor subtypes. Selective antibodies against ADRA1A, ADRA1B and ADRA1D have been successfully reported in few studies. Detection of these proteins in tissue extracts by Western blot analysis has been shown with different rat tissues, including vas deferens and prostate (Manni et al. 2005, 2006, Shen et al. 2000). Immunohistochemical detection of ADRA1A in human prostate (Walden et al. 1999), human peripheral blood lymphocytes (Tayebati et al. 2000) and in different tissues of the male reproductive tract of rats, humans (Queiróz et al. 2008) and rhesus monkeys (Patrão et al. 2008) have also been reported.

Regulation of  $\alpha_1$ -adrenoceptors has been shown to occur under a variety of conditions, including hypoxia, ischemic reperfusion, catecholamine stimulation, cAMP levels, growth factors, hormonal factors and ageing (Markus and Avellar 1997, Zuscik et al. 1999, Gao and Kunos 1993, 1994, Ramarao et al. 1992, Rokosh et al. 1996, Michelotti et al. 2003, Queiróz et al. 2002, Mendes et al. 2004). In fact, changes in androgen status with either sexual maturation or castration differentially regulate the expression of  $\alpha_1$ -adrenoceptor subtypes in several tissues, including the male reproductive tract of different species (MacDonald and MacGrath 1980, Petitti et al. 1992, Shima 1992, Karkianias et al. 1996, Lacey et al. 1996, Pupo 1998, Homma et al. 2000, Queiróz et al. 2002, Quesada and Etgen 2002, Mendes et al. 2004, Campos et al. 2003, Queiróz



#### GPCRS IN THE MALE REPRODUCTIVE TRACT

response to agonist stimulation in the hypothalamus and preoptic area of female rats (Petitti et al. 1992, Karkanas et al. 1996, Quesada and Etgen 2002), suggesting that regulation of  $\alpha_1$ -adrenoceptor by steroid hormones may be dependent on the gender analyzed.

$\alpha_1$ -adrenoceptor antagonists are extensively used in the treatment of hypertension and lower urinary tract symptoms associated with benign prostatic hyperplasia (Roehrborn and Schwinn 2004). Clinical studies have reported ejaculatory dysfunction in patients submitted to treatment with  $\alpha_1$ -adrenoceptor antagonists, especially in those treated with tamsulosin and silodosin, which are selective to  $\alpha_{1A}$ -adrenoceptors (Debruyne 2000, van Dijk et al. 2006). It has been reported that *in vivo* treatment of rats with different  $\alpha_1$ -adrenoceptor antagonists induces a decrease in the ejaculatory capacity associated with a reduction in the fertilization ability of the sperm (Ratnasooriya and Wadsworth 1990, 1994). Recently, Sanbe et al. (2007) have confirmed that the male mouse, with targeted disruption of all  $\alpha_1$ -adrenoceptor subtypes ( $\alpha_1$ -adrenoceptor triple-knockout mouse), is infertile due to an impairment of sperm ejaculation caused by the loss of normal contractility mainly induced by  $\alpha_{1A}$ -adrenoceptor in the vas deferens. However, the fertilization ability of the isolated sperm and sperm motility of these animals are normal.

#### RELAXIN RECEPTORS: EXPRESSION AND FUNCTION IN THE MALE REPRODUCTIVE TRACT

In addition to the influence of steroid hormones and neurotransmitters, the male reproductive tissues are also under control of other factors and hormones. Relaxin is one of the novel peptide hormones which can be important for the normal male reproductive function.

Relaxin is a 6 kDa peptide that belongs to a superfamily of hormones structurally related to insulin, which also includes, among others, the insulin-like growth factors (IGFs) and the insulin-like peptide from Leydig cells (INSL3) (for review see Sherwood 2004). Relaxin was initially detected only in females as a hormone to help parturition, but it has several other functions related or not with the reproductive function (for review see Sher-

uterine contractility and stimulation of mammary growth and differentiation, have been known for time. Recently, several other activities, related with the reproductive function have been attributed to relaxin, including the dilation of blood vessels in several tissues, a positive chronotropic action, the release of histamine from mastocytes, reduction of platelet aggregation, stimulation of thirst and vasopressin secretion, stimulation of prolactin release, and antifibrotic and antiapoptotic effects, to name a few.

In humans, three forms of relaxins (relaxin 1, 2 and 3) are found and they are encoded by three different genes (H1, H2 and H3). The H1 and H2 genes are located in the short arm of the chromosome 9, and probably resulted from gene duplication during the evolution of the primates. The H3 gene is localized in the chromosome 19, near to the gene that encodes INSL3. The H3 gene is expressed in ovary, placenta, decidua and testate gland (Gunnarsen et al. 1996) and the H1 gene is expressed in the last three tissues (Hansell et al. 1991). The recently discovered H3 gene (Bathgate et al. 2002) appears to be mainly expressed in the brain. Although the amino acid sequences of the relaxins H1 and H2 differ considerably, their biological activity is similar, whereas the biological activity of the relaxin H3 is higher.

Only two forms of relaxin have been described in rodents. The relaxin 1 in these animals is encoded by an orthologue of the H2 gene in humans. The relaxin 2 in mouse and rat is derived from an orthologue of the H3 gene (Bathgate et al. 2002, Burazin et al. 2002). The only form of relaxin so far detected in plasma from primates is derived from the H2 gene and its orthologue in various species.

Relaxin was discovered in 1926 by Frederick S. Lewis, who found that the injection of serum from pregnant guinea pigs or rabbits into virgin guinea pigs produced a relaxation of the pubic ligament (Hisaw 1926). The active principle was extracted in 1930 (Fevold 1930), but the purified hormone was only obtained in 1974 (for review see Sherwood 2004). Relaxin is composed of two peptide chains, A and B, which are linked by disulphide bonds. The binding site to the receptor



tial proteolytic digestion of the signal peptide and the peptide that connects the two peptide chains (Ivell and Einspanier 2002).

Although relaxin was discovered a long time ago, the identity of its receptors remained unknown until 2002, when Hsu et al. described that relaxin could bind to and activate the G-protein-coupled receptors (GPCRs) RXFP1 and RXFP2, formerly known as LGR7 and LGR8, respectively. The human relaxins H1 and H2 and porcine relaxin 1 strongly bind to and activate both RXFP1 and RXFP2 with almost the same affinity, but the rat relaxin 1 binds only weakly to RXFP2 (Hsu et al. 2002, Scott et al. 2005). Although relaxin can bind to and activate both the recombinant RXFP1 and RXFP2 expressed in HEK 293 cells (Hsu et al. 2002), it is now recognized that RXFP1 is the endogenous receptor for relaxin, and RXFP2 the endogenous receptor for INSL3 (Zimmermann et al. 1999, Feng et al. 2006).

These two receptors belong to a subfamily of GPCRs, now called leucine-rich repeat-containing GPCRs (LGRs), which also includes the receptors for the gonadotropins LH and FSH, the TSH receptor and the more recently described sea anemone LGR (Nothacker and Grimmelikhuijzen 1993), snail LGR (Tensen et al. 1994), fruit fly LGR1 and LGR2 (Hauser et al. 1997, Nishi et al. 2000), nematode LGR (Kudo et al. 2000) and the LGRs 4, 5 and 6 (Hsu et al. 2000, 2002). Some of these LGRs (LGR 1 to 6) have still unknown ligands. Relaxin 3 binds to RXFP1, but probably its physiological target is the small peptide-like RXFP3 (Liu et al. 2003), the formerly orphan receptor GPCR 135 (for review see Bathgate et al. 2006, Halls et al. 2007).

All members of the LGR subfamily contain a large extracellular amino terminal domain consisting of three subdomains: a N-terminal cysteine-rich subdomain (NCR) followed by a leucine-rich repeat-containing subdomain (LRR subdomain) and a C-terminal cysteine-subdomain (CCR). The leucine-rich repeats in the LRR subdomain presents several  $\beta$ -strands and have been postulated to form a horseshoe shape which is important for hormone binding (Jiang et al. 1995). The CCR subdomain is a hinge region that allows contact between the

guished from other members of the LGR subfamily, and from other GPCRs in general, by a unique low-density lipoprotein class A module (LDL-A) at the aminoterminalus of the ectodomain. Studies with chimeras between RXFP1 and RXFP2 revealed that both the ectodomain and the transmembrane domain of the receptors are necessary for optimal binding and signal transduction (Halls et al. 2005). The unique LDL-A module of RXFP1 and RXFP2 seems crucial for activation of receptor signaling (Scott et al. 2006, Kern et al. 2007).

Relaxin can increase cyclic AMP after interacting with recombinant RXFP1 and RXFP2 in heterologous systems (Hsu et al. 2002, Sudo et al. 2003, Halls et al. 2006). Relaxin can also stimulate endogenous receptors to increase cyclic AMP in many reproductive (Sanborn et al. 1980, Cheah and Sherwood 1980, Judson et al. 1980, Braddon 1978) and non-reproductive tissues (Bathgate et al. 2006), and other downstream signaling reactions can be activated after the production of cyclic AMP, such as tyrosine kinase or mitogen-activated protein kinase activation, and inhibition of phosphodiesterase (for review see Bathgate et al. 2006, Halls et al. 2007). The accumulation of cyclic AMP induced by relaxin in cells that endogenously express RXFP1 involves a time-dependent biphasic pathway: an early phase that involves coupling to  $G_s$ , and a delayed phase that involves activation of PI3K and PKC $\zeta$ . In cells expressing the recombinant RXFP1, studies confirmed this biphasic pattern of cyclic AMP stimulation by relaxin, and showed that the delayed phase involving PI3K and PKC was dependent on  $\beta\gamma$  subunits of the  $G\alpha_{i3}$ . Activation of recombinant RXFP2 by INSL3, on the other hand, involved an initial activation of  $G\alpha_s$  that was modulated by an inhibition mediated by  $G\alpha_{oB}$  and the release of inhibitory  $G\beta\gamma$  subunits (Halls et al. 2006). Therefore, initially both RXFP1 and RXFP2 stimulate cyclic AMP accumulation, but RXFP1 also activates a delayed pathway that further increases cyclic AMP accumulation.

With the recent availability of knockout animals for relaxin or its receptors, it has been possible to establish the physiological importance of this hormone. Relaxin has an antifibrotic effect in several tissues, and the re-



#### GPCRS IN THE MALE REPRODUCTIVE TRACT

metalloproteinases (MMPs) in uterine, cardiac, vascular and renal tissues (Jeyabalan et al. 2003, 2007, Lenhart et al. 2001, Mookerjee et al. 2005).

In the reproductive tract of female mice, the disruption of relaxin or *Rxfp1* gene causes the same abnormalities: an absence of the relaxation and the elongation of the interpubic ligament and impaired nipple development (Zhao et al. 1999, Krajnc-Franken et al. 2004).

The physiological role of relaxin in the male is not so well defined and we will next present some data obtained in our laboratory and from the literature related to the role of relaxin in the male reproductive tissues.

The main evidence of the important role of relaxin for male reproductive function came from observations in transgenic mice with a disruption of relaxin or relaxin receptor genes. In male mice, the disruption of the relaxin gene causes a delayed development of the reproductive tract, with an arrest of sperm maturation (Samuel et al. 2003a), but the disruption of *Rxfp1* does not alter testes or prostate (Kamat et al. 2004), and impairs spermatogenesis and reduces fertility only in the first generations of knockout animals (Krajnc-Franken et al. 2004). The interaction of INSL3 with RXFP2 controls the differentiation of the gubernaculum, the caudal genitoinguinal ligament critical for testicular descent, and deletion of *Insl3* or *Rxfp2* causes cryptorchidism (Zimmermann et al. 1999). Transgenic overexpression of relaxin did not prevent cryptorchidism in *Insl3*-knockout animals (Feng et al. 2006). These observations strongly support the idea that, although both RXFP1 and RXFP2 can bind relaxin *in vitro*, relaxin does not physiologically activate RXFP2. Nevertheless, a contribution of RXFP2 to the actions of relaxin in some species cannot be completely excluded.

The relaxin source in males seems to vary depending on the species. In humans and many other mammals, relaxin is produced by the prostate and released almost exclusively in the seminal fluid. The relaxin mRNA has been detected in human prostate by RT-PCR and *in situ* hybridization (for review see Sherwood 2004, Ivell et al. 1989, Gunnarsen et al. 1996, Bogic et al. 1995). There are few reports on immunohistochemical local-

et al. 1989, Yki-Jarvinen et al. 1983). In other species, the source of the hormone (shark) or seminal vesicle (boar) may be the source of the hormone (Steinetz et al. 1998, Kohlenstein et al. 1992). The source of relaxin in the male rat is controversial. Immunohistochemistry studies have failed to demonstrate relaxin expression in testis, prostate, seminal vesicle and epididymis (Anderson et al. 1988). The mRNA for relaxin has been detected in prostate and testis (Gunnarsen et al. 1995).

Regarding the expression of relaxin receptors in various tissues of the male tract, data available in the literature are scarce. Transcripts for both RXFP1 and RXFP2 have been identified in the whole rat testis (Anand-Ivell et al. 2006, Filonzi et al. 2007), but in primary culture of Sertoli cells only RXFP1 has been found (Filonzi et al. 2007). *Rxfp2* but not *Rxfp1* transcripts are present in Leydig cells. The RXFP1 protein has been detected in elongated spermatids in rat Sertoli cells (Filonzi et al. 2007), and the RXFP2 protein in human Leydig and germ cells (Anand-Ivell et al. 2006). The role of relaxin receptors in the testis remains to be determined. Since RXFP1 and RXFP2 are expressed in germ cells during specific stages of the development, one may speculate that relaxin participates in the spermatogenic process. In addition, the localization of RXFP1 receptors in Sertoli cells suggests that the hormone plays a role in spermatogenesis. However, about the role of relaxin in mature spermatozoa and its effect on sperm motility is controversial. Whereas some data in the literature suggest a role for relaxin in sperm motility (Sarosi et al. 1982, Essig et al. 1982), we detected only low levels of relaxin mRNA in mature spermatozoa, and RXFP1 protein was undetectable (Filonzi et al. 2007). Other studies have also failed to find an effect of relaxin on sperm function (Jockenhovel et al. 1990, Newinger et al. 1990).

The transcripts of *Rxfp1* and *Rxfp2* are present in the caput and cauda regions of the rat epididymis (Filonzi et al. 2007). *Rxfp2* transcripts were also found in the human epididymis (Anand-Ivell et al. 2006). Transcripts of *Rxfp1* and *Rxfp2* have also been identified in the seminal vesicle, but in the prostate only *Rxfp1* mRNA was detected (Filonzi et al. 2007).



2007). Strong immunostaining for RXFP1 and RXFP2 was seen in the apical portion of epithelial cells, in the longitudinal and circular muscular layers, and in the arteriolar wall of blood vessels of the vas deferens. Although relaxin is classically known to reduce uterine tone (Sanborn et al. 1980, for review see Sherwood 2004), it does not affect the contractility of the vas deferens. In this tissue, however, relaxin may be involved in other functions. RXFP1 receptors detected in the arteriolar walls may control local vascular resistance (Filonzi et al. 2007). Furthermore, relaxin increases the expression of metaloproteinase 7 gene in the vas deferens, which may be involved in collagen and matrix remodeling and/or apoptosis (Li et al. 2006). In fact, a significant increase in the collagen expression in the prostate and testis of relaxin knockout mice has been documented before (Samuel et al. 2003a). It remains to be investigated whether RXFP1 receptors in the epithelium of the vas deferens are involved in the regulation of secretion.

### CONCLUSIONS

Muscarinic acetylcholine receptors,  $\alpha_1$ -adrenoceptors and relaxin receptors are often co-localized in tissues of the male reproductive system and may act in concert to regulate several aspects of reproduction. In testis, all subtypes of muscarinic acetylcholine receptors are found in Sertoli cells, where they might counteract FSH-induced cyclic AMP accumulation, influence protein synthesis, cell proliferation and cell junction dynamics. The relaxin receptor RXFP1 expressed in Sertoli cells increases cell proliferation and may also affect protein synthesis, acting in the same direction as FSH. These receptors may therefore indirectly affect spermatogenesis. In addition, RXFP1 is found in late stage germ cells, and muscarinic acetylcholine receptors are found in spermatozoa, supporting their role in spermatogenesis. All these GPCRs are widely distributed in the excurrent ducts of the male tract: efferent ducts, epididymis and vas deferens. Their localization in epithelial cells suggests a role in secretory and absorptive processes, and they may stimulate protein synthesis, therefore affecting sperm composition.

laxin receptor is more likely involved in the architecture of these tissues. Muscarinic acetylcholine receptors and  $\alpha_1$ -adrenoceptors are also involved in events of protein secretion, mitosis, differentiation and smooth muscle contraction in seminal vesicle and prostate.


Although several aspects of muscarinic acetylcholine receptors, with  $\alpha_1$ -adrenoceptors and relaxin receptors have been clarified in the recent years, much still remains to be elucidated about their relative contribution and interaction to control male reproductive function, as well as the mechanisms involved in the regulation of their expression and respective intracellular signaling induced upon activation by a ligand. These studies will certainly provide information that may aid the therapeutics of male infertility and male contraception, since receptors are targets for the development of selective therapeutic agents and pharmacological manipulation of physiological processes.

### ACKNOWLEDGMENTS

The studies conducted in the Section of Experimental Endocrinology and cited in the present review were supported in part by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and the National Institute of Child Health and Human Development/National Institute of Health through cooperative agreement U54-HD35 041 as part of the specialized cooperative Centers Program in Reproduction and by the T.W. Fogarty International Center for Training and Research in Population and Health, USA D43TW/HD00 627 (subcontract UNIFESP/UNC 5-53 284). The authors declare that there is no conflict of interest that could prejudice the impartiality of this work. M.C.W.A. and C.S.P. are research fellows from CNPq. The authors thank Espedita M.J. Silva Santos and Luciana Honda for technical assistance.

### RESUMO

Esta revisão enfatiza a expressão e a função dos receptores muscarínicos, adrenoceptores  $\alpha_1$  e receptores para relaxina.




#### GPCRS IN THE MALE REPRODUCTIVE TRACT

cula seminal e próstata de várias espécies indica o envolvimento destes receptores na modulação da composição do fluido luminal e na contração do músculo liso, incluindo efeitos na fertilidade masculina. Além disso, a ativação dos receptores muscarínicos leva à transativação do receptor para o fator crescimento epidermal e proliferação das células de Sertoli. Os receptores para relaxina estão presentes no testículo, RXFP1 nas espermatídes alongadas e células de Sertoli de rato e RXFP2 nas células de Leydig e germinativas de ratos e humano, sugerindo o envolvimento destes receptores no processo espermatogênico. A localização de ambos os receptores na porção apical das células epiteliais e no músculo liso dos ductos deferentes de rato sugere um papel na contração e na regulação da secreção.

**Palavras-chave:** receptores muscarínicos, adrenoceptores  $\alpha_1$ , receptores para relaxina, sistema reprodutor masculino.

#### REFERENCES

- ABOUT R, SHAFII M AND DOCHERTY JR. 1993. Investigation of the subtypes of  $\alpha_1$ -adrenoceptor mediating contractions in the rat aorta, vas deferens and spleen. *Br J Pharmacol* 109: 80–87.
- ALONSO-LLAMAZARES A, LÓPEZ-ALONSO J, DEL BARRIO M, CASANOVA E, CALVO P AND CHINCHETRU M. 1998. Cloning of chicken and mouse alpha 1b adrenergic receptor. *Biochim Biophys Acta* 1396: 263–266.
- ANAND-IVELL RJ, RELAN V, BALVERS M, COIFFEC-DORVAL I, FRITSCH M, BATHGATE RA AND IVELL R. 2006. Expression of the insulin-like peptide 3 (INSL3) hormone-receptor (LGR8) system in the testis. *Biol Reprod* 74: 945–953.
- ANDERSON MB, COLLADO-TORRES M AND VAUPEL MR. 1986. Absence of relaxin immunostaining in the male reproductive tracts of the rat and mouse. *J Histochem Cytochem* 7: 945–948.
- BAN Y, SATO T, NAKATSUKA T, KEMI M, SAMURA K, MATSUMOTO H, CUKIERSKI MA AND VAN ZWIETEN MJ. 2002. Impairment of male fertility induced by muscarinic receptor antagonists in rats. *Reprod Toxicol* 16: 757–765.
- BATHGATE RA ET AL. 2002. Human relaxina gene 3 (H3) and the equivalent mouse relaxin (M3) gene. *J Biol Chem* 277: 1148–1157.
- of receptors for relaxin family peptides. *Pharmacol Ther* 58: 7–31.
- BERNARD V, LEVEY AI AND BLOCH B. 1999. Regulation of the subcellular distribution of m4 muscarinic acetylcholine receptors in striatal neurons *in vivo* by the cholinergic environment: evidence for regulation of cell surface receptors by endogenous and exogenous stimulation. *J Neurosci* 19: 10237–10249.
- BERNARD V, BRANA C, LISTE I, LOCKRIDGE JF AND BLOCH B. 2003. Dramatic depletion of cell surface muscarinic receptor due to limited delivery from cytoplasmic stores in neurons of acetylcholinesterase deficient mice. *Mol Cell Neurosci* 23: 121–133.
- BHATHAL PS, GERKENS JF AND MASHFORD ML. 1990. Spermatogenic granuloma of the epididymis in rats treated with guanethidine. *J Pathol* 161: 19–26.
- BIRDSALL NJ AND LAZARENO S. 2005. Allosteric modulation of muscarinic receptors: ligands and mechanisms. *Mol Cell Med Chem* 5: 523–543.
- BISHOP MJ. 2007. Recent advances in the discovery of  $\alpha_1$ -adrenoceptor agonists. *Curr Top Med Chem* 7: 135–145.
- BLANCO M AND ROBINSON MJ. 2004. Muscarinic acetylcholine receptor immunostaining in paraffin-embedded normal and neoplastic prostatic gland tissue. *Diagn Pathol* 8: 333–336.
- BOGIC L, MADEL M AND BRYANT-GREENWOOD G. 1995. Relaxin gene expression in human reproductive tissues by *in situ* hybridization. *J Clin Endocrinol Metab* 80: 130–137.
- BORGES MOR, ABREU MLC, PORTO CS AND ABREU MLC. 2001. Characterization of muscarinic acetylcholine receptor in rat Sertoli cells. *Endocrinology* 142: 4710.
- BRADDON SA. 1978. Relaxin-dependent adenosine triphosphatase concentration changes in the mouse symphysis. *Endocrinology* 102: 1292–1299.
- BRODDE OE AND LEINEWEBER K. 2004. Autonomic nervous system in the failing and aging human heart: similarities and differences. *Eur J Pharmacol* 500: 167–177.
- BURAZIN TC, BATHGATE RAD, MACRIS M, LAYE MJ, GUNDLACH AL AND TREGAR GW. 2002. Relaxin-like but abundant expression of the novel rat gene-3 (RLG3) in the dorsal tegmental region of brain. *J Neurosci* 22: 1552–1557.



- an alpha 1B-adrenoceptor mediating contraction of the rat spleen. *Br J Pharmacol* 115: 467–475.
- BURT RP, CHAPPLE CR AND MARSHALL I. 1998. Alpha-1A-adrenoceptor mediated contraction of rat prostatic vas deferens and the involvement of ryanodine stores and  $\text{Ca}^{2+}$  influx stimulated by diacylglycerol and PKC. *Br J Pharmacol* 123: 317–325.
- CAMPOS M, MORAIS PL AND PUPO AS. 2003. Effects of castration and of testosterone replacement on alpha1-adrenoceptor subtypes in the rat vas deferens. *Eur J Pharmacol* 471: 149–156.
- CAULFIELD MP AND BIRDSALL NJM. 1998. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol Rev* 50: 279–290.
- CHALOTHORN D, McCUNE DF, EDELMANN SE, GARCIA-CAZARIN ML, TSUJIMOTO G AND PIASCIK MT. 2002. Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. *Mol Pharmacol* 61: 1008–1016.
- CHAN HC, FU WO, CHUNG YW, ZHOU TS AND WONG PYD. 1994. Adrenergic receptors on cultured rat epididymal cells: regulation of  $\text{Cl}^-$  conductances. *Biol Reprod* 51: 1040–1045.
- CHANG DJ, CHANG TK, YAMANISHI SS, SALAZAR FH, KOSAKA AH, KHARE R, BHAKTA S, JASPER JR, SHIEH IS AND LERNICK JD. 1998. Molecular cloning, genomic characterization and expression of novel human alpha<sub>1A</sub>-adrenoceptor isoforms. *FEBS Lett* 422: 279–283.
- CHATURAPANICH G, MAYTHAARTTAPHONG S, VERAWATANAPAKUL V AND PHOLPRAMOOL C. 2002. Mediation of contraction in rat cauda epididymidis by alpha-adrenoceptors. *Reproduction* 124: 887–892.
- CHEAH SH AND SHERWOOD OD. 1980. Target tissues for relaxin in the rat: tissue distribution of injected 125I-labeled relaxin and tissue changes in adenosine 3',5'-monophosphate levels after *in vitro* relaxin incubation. *Endocrinology* 106: 1203–1209.
- CHEN S, LIN F, IISMAA S, LEE KN, BIRCKBICHLER PJ AND GRAHAM RM. 1996. Alpha1-adrenergic receptor signalling via Gh is subtype specific and independent of its transglutaminase activity. *J Biol Chem* 271: 32385–32391.
- CHEN S, XU M, LIN F, LEE D, RIEK P AND GRAHAM RM. 2000. *Br J Pharmacol* 131: 1–10.
- COGÉ F ET AL. 1999. Truncated isoforms inhibit [ $^3\text{H}$ ] prazosin binding and cellular trafficking of native human  $\alpha_{1A}$ -adrenoceptors. *Biochem J* 343: 231–239.
- DA SILVA MC, GIMENO MF AND GIMENO AL. 1975. Physiologic and pharmacologic studies on the motility of isolated guinea-pig cauda epididymidis. *Fertil Steril* 26: 1250–1256.
- DALY CJ, MILLIGAN CM, MILLIGAN G, MACKENZIE JF AND MCGRATH JC. 1998. Cellular localization and pharmacological characterization of functioning alpha-1 adrenoceptors by fluorescent ligand binding and image analysis reveals identical binding properties of clustered and diffuse populations of receptors. *J Pharmacol Exp Ther* 286: 984–990.
- DANIELS DV ET AL. 1999. Human cloned  $\alpha_{1A}$ -adrenoceptor isoforms display  $\alpha_{1L}$ -adrenoceptor pharmacology in functional studies. *Eur J Pharmacol* 370: 337–343.
- DAVENPORT CW AND HEINDEL JJ. 1987. Cholinergic inhibition of cAMP accumulation in Sertoli cells cultured from immature hamsters. *J Androl* 8: 307–313.
- DEBRUYNE FM. 2000. Alpha blockers: are all created equal? *Urology* 56: 20–22.
- DENG XF, CHEMTOB S AND VARMA DR. 1996. Characterization of  $\alpha_{1D}$ -adrenoceptor subtype in rat myocardium, aorta and other tissues. *Br J Pharmacol* 119: 269–276.
- DIVIANI D, LATTION AL, ABUIN L, STAUB O AND COTECCHIA S. 2003. The adaptor complex 2 directly interacts with the alpha 1b-adrenergic receptor and plays a role in receptor endocytosis. *J Biol Chem* 278: 19331–19340.
- DOCHERTY JR. 1998. Subtypes of functional alpha1- and alpha2-adrenoceptors. *Eur J Pharmacol* 361: 1–15.
- DOCHERTY JR. 2002. Age-related changes in adrenergic neuroeffector transmission. *Auton Neurosci* 96: 8–12.
- DOGGRELL SA. 1986. M1 and M2-muscarinic receptors in the epididymal half of the rat vas deferens. *Gen Pharmacol* 17: 239–241.
- DU JY, ZUO WL, CHEN MH, XIANG H AND ZHOU WL. 2006. Involvement of muscarinic acetylcholine receptors in chloride secretion by cultured rat epididymal epithelium. *Cell Biol Int* 30: 741–746.
- EGLER RM. 2006. Muscarinic receptor subtype in neuronal and non-neuronal cholinergic function. 2006. *Auton Autacoid Pharmacol* 6: 219–233.
- EGLER RM, ADHAM N AND WHITING PJ. 1993. Acetylcholine release from cultured sympathetic neurons: evidence for a role of muscarinic receptors. *J Neurosci* 13: 1000–1010.



GPCRS IN THE MALE REPRODUCTIVE TRACT

- EHRÉN I, SJÖSTRAND NO, HAMMARSTRÖM M AND WIKLUND NP. 1997. Is glandular formation of nitric oxide a prerequisite for muscarinic secretion of fructose in the guinea-pig seminal vesicle? *Urol Res* 25: 433–438.
- EISENHOFER G. 2001. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. *Pharmacol Ther* 91: 35–62.
- ERRASTI AE, AVELLAR MCW, DARAY FM, TRAMONTANO J, LUCIANI LI, LINA BARD MJ, MAROSTICA E AND ROTHLIN RP. 2003. Human umbilical vein vasoconstriction induced by epinephrine acting on  $\alpha 1B$ -adrenoceptor subtype. *Am J Obstet Gynecol* 189: 1472–1480.
- ESBENSHADE TA, HIRASAWA A, TSUJIMOTO G, TANAKA T, YANO J, MINNEMAN KP AND MURPHY TJ. 1995. Cloning of the human  $\alpha 1d$ -adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. *Mol Pharmacol* 47: 977–985.
- ESSIG M, SCHOENFELD C, AMELAR RD, DUBIN L AND WEISS G. 1982. Stimulation of human sperm motility by relaxin. *Fertil Steril* 38: 339–343.
- FENG S, BOGATCHEVA NV, KAMAT AA, TRUONG A AND AGOULNIK AI. 2006. Endocrine effects of relaxin overexpression in mice. *Endocrinology* 147: 407–414.
- FEVOLD HL, HISAW FL AND MEYER RK. 1930. The relaxative hormone of the corpus luteum. Its purification and concentration. *J Am Chem Soc* 52: 3340–3348.
- FILONZI M, CARDOSO LC, PIMENTA MT, QUEIRÓZ DB, AVELLAR MC, PORTO CS AND LAZARI MF. 2007. Relaxin family peptide receptors Rxfp1 and Rxfp2: mapping of the mRNA and protein distribution in the reproductive tract of the male rat. *Reprod Biol Endocrinol* 5: 29.
- FORD APDW, ARREDONDO NF, BLUE DR, BONHAUS DW, JASPER JR, KAVA MS, LESNICK J, PFISTER JR, SHIEH IA AND VIMONT RL. 1996. RS 17053, a selective  $\alpha 1A$  adrenoceptor antagonist, displays low affinity for functional  $\alpha 1A$  adrenoceptors in human prostate: implications for adrenoceptor classification. *Mol Pharmacol* 49: 209–215.
- FORD APDW, DANIELS DV, CHANG DJ, GEVER JR, JASPER JR, LERNICK JD AND CLARKE DE. 1997. Pharmacological pleiotropism of the human recombinant  $\alpha 1A$ -adrenoceptor: implications for  $\alpha 1A$ -adrenoceptor classification. *Br J Pharmacol* 121: 1127–1135.
- ceptor that mediates smooth muscle contraction in prostate has the pharmacological properties of the human  $\alpha 1c$  subtype. *Mol Pharmacol* 45: 703–710.
- FUKASAWA R, TANIGUCHI N, MORIYAMA N, UYAMA Y, YAMAZAKI S, UEKI T, KAMEYAMA S, KIMURA K AND KAWABE K. 1998. The  $\alpha 1L$ -adrenoceptor subtype in the lower urinary tract: a comparison of human prostate and prostate. *Br J Urol* 82: 733–737.
- GAO B AND KUNOS G. 1993. Isolation and characterization of the gene encoding the rat  $\alpha 1B$  adrenergic receptor. *Gene* 131: 243–247.
- GAO B AND KUNOS G. 1994. Transcription of the rat  $\alpha 1B$  adrenergic receptor gene in liver is controlled by multiple promoters. *J Biol Chem* 269: 15762–15767.
- GOBEIL F JR, FORTIER A, ZHU T, BOSSOLAS G, LEDUC M, GRANDBOIS M, HEVEKER N, BKAÏA M, CHEMTOB S AND BARBAZ D. 2006. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. *Can J Physiol Pharmacol* 84: 287–297.
- GONZÁLEZ-ESPINOSA C, ROMERO-ÁVILA T, MORALES-DRÍGUES TM, GONZÁLEZ-ESPINOSA D AND GONZÁLEZ-SÁINS JA. 2001. Molecular cloning and functional expression of the guinea pig  $\alpha 1a$  adrenoceptor. *Eur J Pharmacol* 426: 147–155.
- GRAHAM RM, PEREZ DM, HWA J AND PIASCO V. 1996.  $\alpha 1$ -adrenergic receptor subtypes: molecular structure, function and signalling. *Circ Res* 78: 737–747.
- GRIMM U, FUDER H, MOSER U, BUMERT HG, MÜLLER E AND LAMBRECHT G. 1994. Characterization of the prejunctional muscarinic receptors mediating the evoked release of endogenous noradrenaline from the isolated vas deferens. *Naunyn Schmiedeb. Arch Pharmacol* 349: 1–10.
- GUNNERSSEN JM, CRAWFOR RJ AND TREGEAR GW. 1996. Expression of the relaxin gene in rat tissues. *Mol Endocrinol* 10: 55–64.
- GUNNERSSEN JM, FU P, ROCHE PJ AND TREGEAR GW. 1996. Expression of human relaxin genes: characterization of a novel alternatively-spliced human relaxin gene. *Mol Cell Endocrinol* 118: 85–94.
- HAAG C, BERKELS R, GRÜNDEMANN D, LAZARUS J, TAUBERT D AND SCHOMIG E. 2004. The localization of the extraneuronal monoamine transporter (EMT) in the brain. *J Neurochem* 88: 291–297.





- with  $\alpha 1B$ -adrenergic receptors. *J Biol Chem* 279: 15541–15549.
- HAGUE C, CHEN Z, PUPO AS, SCHULTE N, TOEWS ML AND MINNEMAN K. 2004b. The N-terminus of the human  $\{\alpha\}$ 1D-adrenergic receptor prevents cell surface expression. *J Pharmacol Exp Ther* 309: 388–397.
- HALLS ML, BOND CP, SUDO S, KUMAGAI J, FERRARO T, LAYFIELD S, BATHGATE RA AND SUMMERS RJ. 2005. Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). *J Pharmacol Exp Ther* 313: 677–687.
- HALLS ML, BATHGATE RAD AND SUMMERS RJ. 2006. Relaxin family peptide receptors, RXFP1 and RXFP2, modulate cyclic AMP signalling by distinct mechanisms. *Mol Pharmacol* 70: 214–226.
- HALLS ML, VAN DER WESTHUIZEN ET, BATHGATE RAD AND SUMMERS RJ. 2007. Relaxin family peptide receptors – former orphans reunite with their parent ligands to activate multiple signalling pathways. *Br J Pharmacol* 150: 677–691.
- HAMAMURA M, MARÓSTICA E, AVELLAR MCW AND PORTO CS. 2006. Muscarinic acetylcholine receptor subtypes in the rat seminal vesicle. *Mol Cell Endocrinol* 247: 192–198.
- HANFT G AND GROSS G. 1989. Subclassification of  $\alpha$ 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. *Br J Pharmacol* 97: 691–700.
- HANSELL DJ, BRYANT-GREENWOOD GD AND GREENWOOD FC. 1991. Related Expression of the human relaxin H1 gene in the decidua, trophoblast, and prostate. *J Clin Endocrinol Metab* 72: 899–904.
- HAUSER F, NOTHACKER HP AND GRIMMELIKHUIZEN CJ. 1997. Molecular cloning, genomic organization and developmental regulation of a novel receptor from *Drosophila melanogaster* structurally related to members of the thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone/choriogonadotropin receptor family from mammals. *J Biol Chem* 272: 1002–1010.
- HAWRYLYSHYN KA, MICHELOTTI GA, COGÉ F, GUENIN SP AND SCHWINN DA. 2004. Update on human  $\alpha 1$ -adrenoceptor subtype signalling and genomic organization. *Trends Pharmacol Sci* 25: 449–455.
- HEIN P AND MICHEL MC. 2007. Signal transduction and regulation: are all  $\alpha 1$ -adrenergic receptor subtypes
- HIB J AND CALDEYRO-BARCIA R. 1974. Neurohormonal control of epididymal contractions. In: COUTINHO EM AND FUCHS F (Eds), *PHYSIOLOGY AND GENETIC OF REPRODUCTION, Part B*, New York, Plenum Press, p. 111.
- HIEBLE JP AND RUFFOLO RR JR. 1996. The use of  $\alpha$ -adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. *Pharmacol Res* 33: 145–160.
- HIEBLE JP, BYLUND DB, CLARKE DE, EIKENBURG DC, LANGER SZ, LEFKOWITZ RJ, MINNEMAN KP AND RUFFOLO RR JR. 1995. International Union of Pharmacology. X. Recommendation for nomenclature of  $\alpha$ 1-adrenoceptors: consensus update. *Pharmacol Rev* 47: 267–270.
- HIRASAWA A, SHIBATA K, HORIE K, TAKEY Y, OBIKA K, TANAKA T, MURAMOTO N, TAKAGAKI K, YANO J AND TSUJIMOTO G. 1995. Cloning, functional expression and tissue distribution of human  $\alpha$ 1C-adrenoceptor splice variants. *FEBS Lett* 363: 256–260.
- HIRASAWA A, SUGAWARA T, AWAJI T, TSUMAYA K, ITO H AND TSUJIMOTO G. 1997. Subtype-specific differences in subcellular localization of  $\alpha$ 1-adrenoceptors: chlorethylclonidine preferentially alkylates the accessible cell surface  $\alpha$ 1-adrenoceptors irrespective of the subtype. *Mol Pharmacol* 52: 764–770.
- HIRASAWA A, AWAJI T, XU Z, SHINOURA H AND TSUJIMOTO G. 2001. Regulation of subcellular localization of  $\alpha$ 1-adrenoceptor subtypes. *Life Sci* 68: 2259–2267.
- HISAW FL. 1926. Experimental relaxation of the pubic ligament of the guinea pig. *Proc Soc Exp Biol Med* 23: 661–663.
- HOMMA Y, HAMADA K, NAKAYAMA Y, TSUJIMOTO G AND KAWABE K. 2000. Effects of castration on contraction and  $\alpha$ 1-adrenoceptor expression in rat prostate. *Br J Pharmacol* 131: 1454–1460.
- HORIE K, OBIKA K, FOGLAR R AND TSUJIMOTO G. 1995. Selectivity of the imidazoline  $\alpha$ -adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned  $\alpha$ 1-adrenoceptor subtypes. *Br J Pharmacol* 116: 1611–1618.
- HROMETZ SL, EDELMANN SE, MCCUNE DF, OLGES JR, HADLEY RW, PEREZ DM AND PIASCIK MT. 1999. Expression of multiple  $\alpha$ 1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. *J Pharmacol Exp Ther* 290: 452–463.
- HSU SY, KURO M, CHEN T, NAKAYASHI K, BHALLA A



#### GPCRS IN THE MALE REPRODUCTIVE TRACT

- and LGR7 and the signalling mechanism for LGR7. *Mol Endocrinol* 14: 1257–1271.
- HSU SY, NAKABAYASHI K, NISHI S, KUMAGAI J, KUDO M, SHERWOOD OD AND HSUEH AJ. 2002. Activation of orphan receptors by the hormone relaxin. *Science* 295: 671–674.
- HU K AND NATTEL S. 1995. Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. *Circulation* 92: 2259–2265.
- HULEIHHEL M AND LUNENFELD E. 2004. Regulation of spermatogenesis by paracrine/autocrine testicular factors. *Asian J Androl* 6: 259–268.
- HULME EC, BIRDSALL NJM AND BUCKLEY NJ. 1990. Muscarinic receptor subtypes. *Ann Rev Pharmacol Toxicol* 30: 633–673.
- HWA J AND PEREZ DM. 1996. The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation. *J Biol Chem* 271: 6322–6327.
- HWA J, GRAHAM RM AND PEREZ DM. 1995. Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding. *J Biol Chem* 270: 23189–23195.
- HWA J, GRAHAM RM AND PEREZ DM. 1996. Chimeras of alpha1-adrenergic receptor subtypes identify critical residues that modulate active state isomerization. *J Biol Chem* 271: 7956–7964.
- II M, YAMAMOTO H, ADACHI Y, MARUYAMA Y AND SHINOMURA Y. 2006. Role of metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. *Exp Biol Med* 231: 20–27.
- IRAM S AND HOYLE CH. 2005. Potentiation of sympathetic neuromuscular transmission mediated by muscarinic receptors in guinea pig isolated vas deferens. *Naunyn Schmiedeberg Arch Pharmacol* 371: 212–220.
- IVELL R AND EINSPANIER A. 2002. Relaxin peptides are new global players. *Trends Endocrinol Metab* 13: 343–348.
- IVELL R, HUNT N, KHAN-DAWOOD F AND DAWOOD MY. 1989. Expression of the human relaxin gene in the corpus luteum of the menstrual cycle and in the prostate. *Mol Cell Endocrinol* 66: 251–255.
- JACKSON VM AND CUNNANE TC. 2001. Neurotransmitter release mechanisms in sympathetic neurons: past, present, and future. *Neurosci Biobehav Rev* 25: 1–10.
- and vascular myogenic reactivity of small arteries. *Circulation* 93: 1249–1257.
- JEYABALAN A, NOVAK J, DOTY KD, MATTHEWS VL, FISHER MC, KERCHNER LJ AND CONRAD KL. 2002. Vascular matrix metalloproteinase-9 mediates the regulation of myogenic reactivity in small arteries isolated from rats after short term administration of relaxin. *Endocrinology* 148: 189–197.
- JIANG X, DREANO M, BUCKLER DR, CHENG S, YAN L, A, WU H, HENDRICKSON WA AND EL TAYAR M. 2002. Structural predictions for the ligand-binding region of the relaxin receptor: implications for the interaction of coprotein hormone receptors and the nature of hormone-receptor interactions. *Structure* 3: 1341–1353.
- JOCKENHOVEL F, ALTENSELL A AND NIESCHLAG J. 2002. Active immunization with relaxin does not influence the subjectively determined sperm motility in rabbits. *Andrologia* 22: 171–178.
- JUDSON DG, PAY S AND BHOOLA KD. 1980. Modulation of cyclic AMP in isolated rat uterine tissue slices by relaxin. *J Endocrinol* 87: 153–159.
- JURKIEWICZ NH, CARICATI-NETO A, VERDE LF, LAR MCW, REUTER HR AND JURKIEWICZ A. 1995. Sympathetic neurotransmission in the rat testis: functional characterization and identification of mRNA encoding alpha1-adrenoceptor subtypes. *Pharmacol* 43: 141–150.
- KAMAT AA, FENG S, BOGATCHEVA NV, TRUONG B, BISHOP CE AND AGOULNIK AI. 2004. Genetic regulation of relaxin and insulin-like factor 3 receptors. *Endocrinology* 145: 4712–4720.
- KARKANIAS GB, ANSONOFF MA AND ETGEN AM. 2002. Estradiol regulation of alpha 1b-adrenoceptor mRNA in the female rat hypothalamus-preoptic area. *J Neuroendocrinol* 8: 449–455.
- KERN A, AGOULNIK AI AND BRYANT-GREENWOOD G. 2007. The low-density lipoprotein class A modulator relaxin receptor (leucine-rich repeat containing G protein-coupled receptor 7): its role in signalling and trafficking to the cell membrane. *Endocrinology* 148: 1181–1190.
- KIM JK, KIM SJ, LEE JE, MIN KM AND KIM SJ. 2002. A subtype of muscarinic receptors mediate Ca<sup>2+</sup> release from intracellular stores in rat prostatic neuroendocrine cells. *Korean Med Sci* 20: 256–261.
- KINGHORN EM, BATE AS AND HIGGINS SJ. 1987. The effect of relaxin on the contractility of rat seminal vesicle epithelial cells in culture. *J Reprod Fertil* 68: 1–10.




- KOHSAKA T, TAKAHARA H, SASADA H, KAWARASAKI T, BAMBA K, MASAKI J AND TAGAMI S. 1992. Evidence for immunoreactive relaxin in boar seminal vesicles using combined light and electron microscope immunocytochemistry. *J Reprod Fertil* 95: 397–408.
- KONDO S, TASHIMA Y AND MORITA T. 1994. Segmental differences in the density of autonomic receptors in dog vas deferens. *Urol Int* 53: 62–67.
- KRAJNC-FRANKEN MA, VAN DISSELDORP AJ, KOENDERS JE, MOSSELMAN S, VAN DUIN M AND GOSSEN JA. 2004. Impaired nipple development and parturition in LGR7 knockout mice. *Mol Cell Biol* 24: 687–696.
- KUBO T, FUKUDA K, MIKAMI A, MAEDA A, TAKAHASHI H, MISHINA M, HAGA T, HAGA K, ICHIYAMA A AND KANGAWA K. 1986. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. *Nature* 323: 411–416.
- KUDO M, CHEN T, NAKABAYASHI K, HSU SY AND HSUEH AJW. 2000. The nematode leucine-rich repeat-containing, G protein-coupled receptor LGR protein homologous to vertebrate gonadotropin and thyrotropin receptors is constitutively activated in mammalian cells. *Mol Endocrinol* 14: 272–284.
- LACEY JP, DONATUCCI CF, PRICE DT, PAGE SO, BENNETT SA, TENNISWOOD MP AND SCHWINN DA. 1996. Effects of androgen deprivation on prostate alpha 1-adrenergic receptors. *Urology* 48: 335–341.
- LANGER S. 1999. History and nomenclature of alpha 1 adrenoceptors. *Eur Urol* 36: 2–6.
- LANZAFAME AA, CHRISTOPOULOS A AND MITCHELSON F. 2003. Cellular signalling mechanism for muscarinic acetylcholine receptors. *Receptor Channel* 9: 241–260.
- LAU WA AND PENNEFATHER JN. 1998. Muscarinic receptor subtypes in the rat prostate gland. *Eur J Pharmacol* 343: 151–156.
- LAZ TM, FORRAY C, SMITH KE, BARD JA, VAYSSE PJ, BRANCHEK TA AND WEINSHANK RL. 1994. The rat homologue of the bovine alpha 1c-adrenergic receptor shows the pharmacological properties of the classical alpha 1A subtype. *Mol Pharmacol* 46: 414–422.
- LEEB-LUNDBERG LM, COTECCHIA S, LOMASNEY JW, DEBERNARDIS JF, LEFKOWITZ RJ AND CARON MG. 1985. Phorbol esters promote alpha 1-adrenergic receptor phosphorylation and receptor uncoupling from inositol roles for receptor kinases and beta-arrestins in receptor signalling and desensitization. *J Biol Chem* 273: 18677–18680.
- LEFKOWITZ RJ AND CARON MG. 1988. Adrenergic receptors. Models for the study of receptors coupled to guanine nucleotide regulatory proteins. *J Biol Chem* 263: 4993–4996.
- LEFKOWITZ RJ, PITCHER J, KRUEGER K AND DAAKA Y. 1998. Mechanisms of beta-adrenergic receptor desensitization and resensitization. *Adv Pharmacol* 42: 416–420.
- LENHART JA, RYAN PL, OHLETH KM, PALMER SS AND BAGNELL CA. 2001. Relaxin increases secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 during uterine and cervical growth and remodeling in the pig. *Endocrinology* 142: 3941–3949.
- LEPOR H, ZHANG W, KOBAYASHI S, TANG R, WANG B AND SHAPIRO E. 1994. A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. *J Pharmacol Exp Ther* 270: 722–727.
- LEUNG AYH, YIP WK AND WONG PYD. 1992. Characterization of adrenoceptors involved in the electrogenic chloride secretion by cultured rat epididymal epithelium. *Br J Pharmacol* 107: 146–151.
- LIU C, ERISTE E, SUTTON S, CHEN J, ROLAND B, KUEI C, FARMER N, JÖRNVALL H, SILLARD R AND LOVENBERG TW. 2003. Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. *J Biol Chem* 278: 50754–50764.
- LOCKWOOD DH AND WILLIAMS-ASHMAN HG. 1971. Cholinergic-stimulated alkaline phosphatase secretion and phospholipid synthesis in guinea pig seminal vesicles. *J Cell Physiol* 77: 7–15.
- LONGHURST PA AND BROTCHE TP. 1989. Effects of castration and *diabetes mellitus* on cholinergic responsiveness and muscarinic receptors in the rat vas deferens. *J Urol* 141: 1225–1229.
- LOPEZ-GIMENEZ JF, CANALS M, PEDIANI JD AND MILLIGAN G. 2007. The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function. *Mol Pharmacol* 71: 1015–1029.
- LUCAS TFG, AVELLAR MCW AND PORTO CS. 2004. Effects of carbachol on rat Sertoli cell proliferation and muscarinic acetylcholine receptors regulation: an *in vitro*



#### GPCRS IN THE MALE REPRODUCTIVE TRACT

- acetylcholine receptors: relevance to infertility and male contraception. *Immun, Endoc & Metab, Agents in Med Chem* 8: 42–50.
- LUTHIN GR, WANG P, ZHOU H, DHANASEKARAN D AND RUGGIERI MR. 1997. Role of m1 receptor-G protein coupling in cell proliferation in the prostate. *Life Sci* 60: 963–968.
- MACDONALD A AND MCGRATH JC. 1980. The effects of castration on neurotransmission in the rat vas deferens. *Br J Pharmacol* 69: 49–58.
- MACKENZIE JF, DALY CJ, PEDIANI JD AND MCGRATH JC. 2000. Quantitative imaging in live human cells reveals intracellular  $\alpha_1$ -adrenoceptor ligand-binding sites. *J Pharmacol Exp Ther* 294: 434–443.
- MACKINNON AC, SPEDDING M AND BROWN CM. 1994. Alpha 2-adrenoceptors: more subtypes but fewer functional differences. *Trends Pharmacol Sci* 15: 119–123.
- MALLARD NJ, MARSHALL RW, SITHERS AJ AND SPRIGGS TL. 1992. Separation of putative alpha 1A- and alpha 1B-adrenoceptor mediated components in the tension response of the rat vas deferens to electrical field stimulation. *Br J Pharmacol* 105: 727–731.
- MANNI L, HOLMANG A, LUNDEBERG T, ALOE L AND STENER-VICTORIN E. 2005. Ovarian expression of alpha (1)- and beta (2)-adrenoceptors and p75 neurotrophin receptors in rats with steroid-induced polycystic ovaries. *Auton Neurosci* 118:79–87.
- MANNI L, HOLMANG A, CAJANDER S, LUNDEBERG T, ALOE L AND STENER-VICTORIN E. 2006. Effect of anti-NGF on ovarian expression of alpha1- and beta2-adrenoceptors, TrkA, p75NTR, and tyrosine hydroxylase in rats with steroid-induced polycystic ovaries. *Am J Physiol Regul Integr Comp Physiol* 290: R826–R835.
- MARKUS RP AND AVELLAR MCW. 1997. Age-related changes in the reactivity of postsynaptic adrenoceptors in the rat vas deferens: differences between the epididymal and prostatic portion. *Auton Pharmacol* 17: 147–154.
- MARÓSTICA E, GUAZE EF, AVELLAR MCW AND PORTO CS. 2001. Characterization of muscarinic acetylcholine receptors in rat epididymis. *Biol Reprod* 65: 1120–1126.
- MARÓSTICA E, AVELLAR MCW AND PORTO CS. 2005. Effects of testosterone on muscarinic acetylcholine receptors in the rat epididymis. *Life Sci* 77: 656–669.
- MCCUNE DF, EDELMANN SE, OLGES JR, POST GR, WALDROP RA, WAUGH DJ, PEREZ DM AND PIASCIK MT, MCCUNE SK AND HILL JM. 1995. Ontogenic expression of two alpha-1 adrenergic receptor subtypes in the rat. *J Mol Neurosci* 6: 51–62.
- MENDES FR, HAMAMURA M, QUEIRÓZ DB, PORTO CS AND AVELLAR MCW. 2004. Effects of androgen regulation on alpha1-adrenoceptor subtypes in the rat vesicle. *Life Sci* 75: 1449–1463.
- MICHELOTTI GA, PRICE DT AND SCHWINN DA. 2000. Alpha 1 adrenergic receptor regulation: basic science and clinical implications. *Pharmacol Ther* 88: 281–300.
- MICHELOTTI GA, BAUMAN MJ, SMITH MJ AND SCHWINN DA. 2003. Cloning and characterization of the rat alpha 1a-adrenergic receptor gene promoter: demonstration of cell specificity and regulation by histamine. *J Biol Chem* 278: 8693–8705.
- MIRANDA HF, BUSTAMANTE D, CASTILLO O, CASTAÑEDA TIERRA P, SAAVEDRA H, FERNANDEZ E, PAEILEN T, PELISSIER T AND PINARDI G. 1992. Cholinergic receptors in the human vas deferens. *J Recept Res* 12: 1–10.
- MIRANDA HF, DURAN E, BUSTAMANTE D, PAEILEN T AND PINARDI G. 1994. Pre- and postjunctional muscarinic receptor subtypes in the vas deferens of rat. *Gen Pharmacol* 25: 1643–1647.
- MIRANDA HF, DURAN E, FERNANDEZ E AND PINARDI G. 1995. Muscarinic receptor subtypes in the bisection of the rat vas deferens. *Gen Pharmacol* 26: 387–391.
- MOOKERJEE I, UNEMORI EN, DU XJ, TREGGART G AND SAMUEL CS. 2005. Relaxin modulates fibroblast proliferation, collagen production and matrix metalloproteinase expression by cardiac fibroblasts. *Ann NY Acad Sci* 1056: 190–193.
- MORIYAMA N, KURIMOTO S, HORIE S, NASU K, TATEYAMA T, YANO K, HIRANO H, TSUJIMOTO G AND KAWABATA K. 1996. Detection of alpha 1-adrenoceptor subtypes in human hypertrophied prostate by *in situ* hybridization. *Histochem J* 28: 283–288.
- MORROW AL AND CREESE I. 1986. Characterization of alpha 1-adrenergic receptor subtypes in rat brain: autoradiographic evaluation of [<sup>3</sup>H]WB4104 and [<sup>3</sup>H]prazosin binding. *Pharmacol* 29: 321–330.
- MURAMATSU I, OSHITA M, OHMURA T, KAWABATA S, AKINO H, GOBARA M AND OKADA K. 1999. Pharmacological characterization of  $\alpha_1$ -adrenoceptor subtypes in the human prostate: functional and binding studies.



- effects of protein kinase C activation on the human cardiac  $\text{Na}^+$  channel. *Circ Res* 80: 370–376.
- NADELHAFT I. 2003. Cholinergic axons in the rat prostate and neurons in the pelvic ganglion. *Brain Res* 989: 52–57.
- NAKAOKA H, PEREZ DM, BAEK KJ, DAS T, HUSAIN A, MISONO K, IM MJ AND GRAHAM RM. 1994. Gh: a GTP-binding protein with transglutaminase activity and receptor signalling function. *Science* 264: 1593–1596.
- NASU K, MORIYAMA N, KAWABE K, TSUJIMOTO G, MURAI M, TANAKA T AND YANO J. 1996. Quantification and distribution of  $\alpha_1$ -adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. *Br J Pharmacol* 119: 797–803.
- NASU K, MORIYAMA N, FUKASAWA R, TSUJIMOTO G, TANAKA T, YANO J AND KAWABE K. 1998. Quantification and distribution of  $\alpha_1$ -adrenoceptor subtype mRNAs in human proximal urethra. *Br J Pharmacol* 123: 1289–1293.
- NEWINGER J, JOCKENHOVEL F AND NIESCHLAG E. 1990. The influence of relaxin on motility of human sperm *in vitro*. *Andrologia* 22: 335–339.
- NISHI S, HSU SY, ZELL K AND HSUEH AJW. 2000. Characterization of two fly LGR (Leucine-Rich Repeat-containing, G protein-coupled receptor) proteins homologous to vertebrate glycoprotein hormone receptors: constitutive activation of wild-type fly LGR1 but not LGR2 in transfected mammalian cells. *Endocrinology* 141: 4081–4090.
- NOTHACKER HP AND GRIMMELIKHUIZEN CJP. 1993. Molecular cloning of a novel putative G protein-coupled receptor from sea anemones structurally related to members of the FSH, TSH, LH/CG receptor family from mammals. *Biochem Biophys Res Commun* 197: 1062–1069.
- OBARA K, ARAI K, MIYAJIMA N, HATANO A, TOMITA Y AND TAKAHASHI K. 2000. Expression of m2 muscarinic acetylcholine receptor mRNA in primary culture of human prostate stromal cells. *Urol Res* 28: 196–200.
- PAPATSORIS AG, KARAMOZIS MV AND PAPAVALASSIOU AG. 2007. The power and promise of “rewiring” the mitogen-activated protein kinase network in prostate cancer therapeutics. *Mol Cancer Ther* 6: 811–819.
- PATRÃO MT, QUEIRÓZ DB, LÁZARI MF AND AVELLAR MCW. 2008. Cloning, expression and immunolocalization of  $\alpha_1$ -adrenoceptor in different tissues from rhesus monkey and human male reproductive tract. *Mol Hum*
- using homology modeling and molecular docking. *Biochem Biophys Res Commun* 319: 493–500.
- PEREZ DM, PIASCIK MT, MALIK N, GAIVIN R AND GRAHAM RM. 1994. Identification of the mRNA for the novel  $\alpha_1$ -adrenoceptor and two other  $\alpha_1$ -adrenoceptors in vascular smooth muscle. *Mol Pharmacol* 46: 823–831.
- PETITTI N, KARKANAS GB AND ETGEN AM. 1992. Estradiol selectivity regulates  $\alpha_1$ -noradrenergic receptors in the hypothalamus and preoptic area. *J Neurosci* 12: 3869–3876.
- PIASCIK MT AND PEREZ DM. 2001.  $\alpha_1$ -adrenergic receptors: new insights and directions. *J Pharmacol Exp Ther* 298: 403–410.
- PIASCIK MT, GUARINO RD, SMITH MS, SOLTIS EE, SAUSSY DL AND PEREZ DM. 1995. The specific contribution of the novel  $\alpha_1$ -adrenoceptor to the contraction of vascular smooth muscle. *J Pharmacol Exp Ther* 275: 1583–1589.
- PIASCIK MT, HROMETZ SL, EDELMANN SE, GUARINO RD, HADLEY RW AND BROWN RD. 1997. Immunocytochemical localization of the  $\alpha_1$ -adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides. *J Pharmacol Exp Ther* 283: 854–868.
- PONTARI MA, LUTHIN GR, BRAVERMAN AS AND RUGGIERI MR. 1998. Characterization of muscarinic cholinergic receptor subtypes in rat prostate. *J Recept Signal Transduct Res* 18: 151–166.
- PORTER JE, HWA J AND PEREZ DM. 1996. Activation of the  $\alpha_1$ -adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. *J Biol Chem* 271: 28318–28323.
- PRENZEL N, ZWICK E, DAUB H, LESERE M, ABRAHAM R, WALLASCH C AND ULRICH A. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. *Nature* 402: 884–888.
- PRICE DT, CHARI RS, BERKOWITZ DE, MEYERS WC AND SCHWINN DA. 1994a. Expression of  $\alpha_1$ -adrenergic receptor subtype mRNA in rat tissues and human SK-N-MC neuronal cells: implications for  $\alpha_1$ -adrenergic receptor subtype classification. *Mol Pharmacol* 46: 221–




#### GPCRS IN THE MALE REPRODUCTIVE TRACT

- three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. *Mol Pharmacol* 45: 171–175.
- PRICE RR, MORRIS DP, BISWAS G, SMITH MP AND SCHWINN DA. 2002. Acute agonist-mediated desensitization of the human alpha 1a-adrenergic receptor is primarily independent of carboxyl terminus regulation: implications for regulation of alpha 1a-AR splice variants. *J Biol Chem* 277: 9570–9579.
- PUPPO AS. 1998. Functional effects of castration on  $\alpha_1$ -adrenoceptors in rat vas deferens. *Eur J Pharmacol* 351: 217–223.
- PUPPO AS AND MINNEMAN KP. 2003. Specific interactions between gC1qR and alpha1-adrenoceptor subtypes. *J Recept Signal Transduct Res* 23: 185–195.
- QUEIRÓZ DB, PORTO CS, GROSSMAN G, PETRUSZ P AND AVELLAR MCW. 2008. Immunolocalization of alpha(1A)-adrenoceptors in rat and human epididymis. *Cell Tissue Res* 332: 509–522.
- QUEIRÓZ DBC, MENDES FR, PORTO CS AND AVELLAR MCW. 2002. Alpha1-adrenoceptor subtypes in rat epididymis and the effects of sexual maturation. *Biol Reprod* 66: 508–515.
- QUESADA A AND ETGEN AM. 2002. Functional interactions between estrogen and insulin-like growth factor-1 in the regulation of alpha1B-adrenoceptors and female reproductive function. *J Neuroscience* 22: 2401–2408.
- RAMARAO CS, DENKER JM, PEREZ DM, GAIVIN RJ, RIEK RP AND GRAHAM RM. 1992. Genomic organization and expression of the human alpha 1B-adrenergic receptor. *J Biol Chem* 267: 21936–21945.
- RAMSAY D, CARR IC, PEDIANI J, LOPEZ-GIMENEZ JF, THURLOW R, FIDOCK M AND MILLIGAN G. 2004. High-affinity interactions between human alpha1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the alpha1L-adrenoceptor. *Mol Pharmacol* 66: 228–239.
- RATNASOORIYA WD AND WADSWORTH RM. 1990. Impairment of fertility of male rats with prazosin. *Contraception* 41: 441–447.
- RATNASOORIYA WD AND WADSWORTH RM. 1994. Tamulosin, a selective  $\alpha_1$  adrenoceptor antagonist, inhibits fertility of male rats. *Andrologia* 26: 107–110.
- RAYFORD W, NOBLE MJ, AUSTENFELD MA, WEIGEL J, RICKER DD, CHAMNESS SL, HINTON BT AND TSK. 1996. Changes in luminal fluid protein composition in the rat cauda epididymidis following partial sympathetic denervation. *J Androl* 17: 117–126.
- ROEHRBORN CG AND SCHWINN DA. 2004. Alpha-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. *J Urol* 172: 1029–1035.
- ROKOSH DG, BAILEY BA, STEWARD AFR, KARLINER JS, LONG CS AND SIMPSON PC. 1994. Distribution of alpha1-adrenergic receptor mRNA in adult rat tissues by Northern blot, in situ hybridization, and Northern blot protection assay and comparison with  $\alpha_{1B}$  and  $\alpha_{1C}$  subtypes. *J chem Biophys Res Commun* 200: 1177–1184.
- ROKOSH DG, STEWART AF, CHANG KC, BAILEY BA, KARLINER JS, CAMACHO SA, LONG CS AND SIMPSON PC. 1996. Alpha1-adrenergic receptor subtypes and their mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes: *in vitro* and *in vivo*. Repression of alpha1B and alpha1C subtypes and induction of alpha1C. *J Biol Chem* 271: 5839–5844.
- RUDNER XL, BERKOWITZ DE, BOOTH JV, FURUKAWA T, COZART KL, D’AMICO EB, EL-MOALEM H, KARLINER JS, SO, RICHARDSON CD AND WINTERS B. 1999. Alpha1-adrenergic receptor type specific regulation of human vascular alpha1-adrenergic receptors by vessel bed and age. *Circulation* 100: 2336–2343.
- RUFFOLO RR JR AND HIEBLE JP. 1999. Adrenoceptor pharmacology: urogenital applications. *Eur Urol* 36: 1–10.
- RUGGIERI MR, COLTON MD, WANG P, SMYTH GT, PONTARI MA AND LUTHIN GR. 1995. Human muscarinic receptor subtypes. *J Pharmacol Exp Ther* 274: 976–982.
- SALAMANCA AE, SIEMASKO KF, DIEBOLD Y, CAMACHO SA, GAO J, JUÁREZ-CAMPO M AND STERN MI. 1999. Expression of muscarinic and adrenergic receptors in the human conjunctival epithelium. *Invest Ophthalmol Vis Sci* 40: 504–513.
- SALLÉS J AND BADIA A. 1991. Mechanisms underlying the differential sensitivity to alpha 1-adrenoceptor agonists in the bisected rat vas deferens. *Br J Pharmacol* 103: 445.
- SAMUEL CS, TIAN H, ZHAO L AND AMENTO EP. 1999. Relaxin is a key mediator of prostate growth and development of the reproductive tract. *Lab Invest* 83: 1029–1035.




- TREGGAR GW. 2003b. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. *FASEB J* 17: 121–123.
- SAMUEL CS, ZHAO C, BATHGATE RAD, DU XJ, SUMMERS RJ, AMENTO EP, WALKER LL, MCBURNIE M, ZHAO L AND TREGGAR GW. 2005. The relaxin gene-knockout mouse: a model of progressive fibrosis. *Ann NY Acad Sci* 1041: 173–181.
- SANBE A, TANAKA Y, FUJIWARA Y, TSUMURA H, YAMAUCHI J, COTECCHIA S, KOIKE K, TSUJIMOTO G AND TANOUE A. 2007. Alpha-1 adrenoceptor is required for normal male sexual function. *Br J Pharmacol* 52: 332–340.
- SANBORN BM, KUO HS, WEISBRODT NW AND SHERWOOD OD. 1980. The interaction of relaxin with the rat uterus. I. Effect on cyclic nucleotide levels and spontaneous contractile activity. *Endocrinology* 106: 1210–1215.
- SAROSI P, SCHOENFELD C, BERMAN J, BASCH R, RANDOLPH G, AMELAR R, DUBIN L, STEINETZ BG AND WEISS G. 1983. Effect of anti-relaxin antiserum on sperm motility *in vitro*. *Endocrinology* 112: 1860–1861.
- SATO T, BAN Y, UCHIDA M, GONDO E, YAMAMOTO M, SEKIGUCHI Y, SAKAUE A, KEMI M AND NAKATSUKA T. 2005. Atropine-induced inhibition of sperm and semen transport impairs fertility in male rats. *J Toxicol Sci* 30: 207–212.
- SAUSSY DL JR, GOETZ AS, QUEEN KL, KING HK, LUTZ MW AND RIMELE TJ. 1996. Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. *J Pharmacol Exp Ther* 278: 136–144.
- SAWUTZ DG, LANIER SM, WARREN CD AND GRAHAM RM. 1987. Glycosylation of the mammalian alpha 1-adrenergic receptor by complex type N-linked oligosaccharides. *Mol Pharmacol* 32: 565–571.
- SCARPARO AC, SUMIDA DH, PATRÃO MTCC, AVELLAR MCW, VISCONTI MA AND CASTRUCCI MA. 2004. Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors. *Arch Dermatol Res* 296: 112–119.
- SCHWINN DA AND KWATRA MM. 1998. Expression and regulation of alpha 1-adrenergic receptors in human tissues. *Adv Pharmacol* 42: 390–394.
- and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. *J Biol Chem* 265: 8183–8189.
- SCOFIELD MA, LIU F, ABEL PW AND JEFFRIES WB. 1995. Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction. *J Pharmacol Exp Ther* 275: 1035–1042.
- SCOTT DJ, LAYFIELD S, REISEWIJK A, MORITA H, TREGGAR GW AND BATHGATE RAD. 2005. Characterisation of the mouse and rat relaxin receptors. *Ann NY Acad Sci* 1041: 8–12.
- SCOTT DJ, LAYFIELD S, YAN Y, SUDO S, HSUEH AJ, TREGGAR GW AND BATHGATE RA. 2006. Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signalling is mediated by their unique low density lipoprotein class A modules. *J Biol Chem* 281: 34942–34954.
- SHANNON HE, SAWYER BD, BEMIS KG, BYMASTER FP, HEALTH I, MITCH CH AND WARD JS. 1993. Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens. *Eur J Pharmacol* 232: 47–57.
- SHAPIRO E, MILLER AR AND LEPOR H. 1985. Down-regulation of the muscarinic cholinergic receptor of the rat prostate following castration. *J Urol* 134: 179–182.
- SHEN H, PERI KG, DENG XF, CHEMTOB S AND VARMA DR. 2000. Distribution of  $\alpha_1$ -adrenoceptor subtype proteins in different tissues of neonatal and adult rats. *Can J Physiol Pharmacol* 78: 237–243.
- SHERWOOD OD. 2004. Relaxin’s physiological roles and other diverse actions. *Endocrine Rev* 25: 205–234.
- SHIMA S. 1992. Effects of androgen on  $\alpha$ - and  $\beta$ -adrenergic receptors in membranes from the rat seminal vesicle. *Biochim Biophys Acta* 1175: 123–127.
- SHINOUE H, SHIBATA K, HIRASAWA A, TANOUE A, HASHIMOTO K AND TSUJIMOTO G. 2002. Key amino acids for differential coupling of alpha1-adrenergic receptor subtypes to Gs. *Biochem Biophys Res Comm* 299: 142–147.
- SILVA MA, MEGALE A, AVELLAR MCW AND PORTO CS. 1999. Expression and pharmacological characterization of  $\alpha_1$ -adrenoceptors in rat seminal vesicle. *Eur J Pharmacol* 381: 141–149.
- SU ER, YASUHARA F, MARÓSTICA E, AVELLAR MCW AND PORTO CS. 2006. Expression and localization



#### GPCRS IN THE MALE REPRODUCTIVE TRACT

- SKINNER MK. 2005. Sertoli cell secreted regulatory factors. In: SKINNER MK AND GRISWOLD MD (Eds), SERTOLI CELL BIOLOGY, Elsevier Science, San Diego, USA, p. 107–120.
- SOKOL RZ, WANG XS, LECHAGO J, JOHNSTON PD AND SWERDLOFF RS. 1989. Immunohistochemical localization of relaxin in human prostate. *J Histochem* 37: 1253–1255.
- STEINETZ BG, SCHWABE C, CALLARD IP AND GOLD-SMITH LT. 1998. Dogfish shark (*Squalus acanthias*) testes contain a relaxin. *J Androl* 19: 110–115.
- SUDO S, KUMAGAI J, NISHI S, LAYFIELD S, FERRARO T, BATHGATE RA AND HSUEH AJ. 2003. H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. *J Biol Chem* 278: 7855–7862.
- SUGAWARA T, HIRASAWA A, HASHIMOTO K AND TSUJIMOTO G. 2002. Differences in the subcellular localization of  $\alpha$ 1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. *Life Sci* 70: 2113–2124.
- SUZUKI F, TANIGUCHI T, TAKAUJI R, MURATA S AND MURAN I. 2000. Splice isoforms of  $\alpha_{1a}$  adrenoceptor in rabbit. *Br J Pharmacol* 129: 1569–1576.
- TAYEBATI SK, BRONZETTI E, MORRA DI CELLA S, MULATERO P, RICCI A, ROSSODIVITA I, SCHENA M, SCHIAVONE D, VEGLIO F AND AMENTA F. 2000. *In situ* hybridization and immunocytochemistry of  $\alpha_1$ -adrenoceptors in human peripheral blood lymphocytes. *J Auton Pharmacol* 20: 305–312.
- TENG CM, GUH JH AND KO FN. 1994. Functional identification of  $\alpha$ 1-adrenoceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen. *Eur J Pharmacol* 265: 61–66.
- TENSEN CP, VAN KESTEREN ER, PLANTA RJ, COX KJ, BURKE JF, VAN HEERIKHUIZEN H AND VREUGDENHIL E. 1994. A G protein-coupled receptor with low density lipoprotein-binding motifs suggests a role for lipoproteins in G-linked signal transduction. *Proc Natl Acad Sci USA* 91: 4816–4820.
- TESTA R, GUARNERI L, TADDEI C, POGGESI E, ANGELICO P, SARTANI A, LEONARDI A, GOFRIT ON, MERETYK S AND CAINE M. 1996. Functional antagonistic activity of Rec 15/2739, a novel  $\alpha$ 1-adrenergic antagonist selective for
- THEBAULT S, ZHOLOS A, ENFISSI A, SLOMIANNY WAILLY E, ROUDBARAKI M, PARYS J AND PRADY KAYA N. 2005. Receptor-operated  $\text{Ca}^{2+}$  entry mediated by TRPC3/TRPC6 proteins in rat prostate smooth muscle (PS1) cell line. *J Cell Physiol* 204: 320–328.
- THEROUX TL, ESBENSHADE TA, PEAVY RD AND MINNEMAN KP. 1996. Coupling efficiencies of human  $\alpha_1$ -adrenergic receptor subtypes: titration of receptor expression and responsiveness with inducible and repressible expression vectors. *Mol Pharmacol* 50: 1376–1387.
- TOEWS ML, PRINSTER SC AND SCHULTE NA. 2000. Regulation of  $\alpha$ 1B-adrenergic receptor localization, trafficking, function, and stability. *Life Sci* 74: 379–388.
- UBERTI MA, HALL RA AND MINNEMAN KP. 2000. Subtype-specific dimerization of  $\alpha_1$ -adrenoceptors affects on receptor expression and pharmacological properties. *Mol Pharmacol* 64: 1379–1390.
- UBERTI MA, HAGUE C, OLLER H, MINNEMAN KP AND HALL RA. 2005. Heterodimerization with  $\beta_2$ -adrenergic receptors promotes surface expression and functional activity of  $\alpha_1$ D-adrenergic receptors. *J Pharmacol Exp Ther* 313: 16–23.
- VAN DIJK MM, DE LA ROSETTE JJ AND MICHEL MO. 2000. Effects of  $\alpha_1(1)$ -adrenoceptor antagonists on myocardial function. *Drugs* 66: 287–301.
- VAN KOPPEN CJ AND KAISER B. 2003. Regulation of muscarinic acetylcholine receptor signalling. *Pharmacol Ther* 98: 197–220.
- VARMA DR AND DENG XF. 2000. Cardiovascular effects of  $\alpha_1$ -adrenoceptor subtypes: functions and signalling. *Physiol Pharmacol* 78: 267–292.
- VÁZQUEZ-PRADO J, MEDINA LC, ROMERO-AVILA J, GONZALEZ-ESPINOSA C AND GARCIA-SAINZ J. 2000. Norepinephrine- and phorbol ester-induced phosphorylation of  $\alpha_1(1a)$ -adrenergic receptors. Functional aspects. *J Biol Chem* 275: 6553–6559.
- VENTURA S, PENNEFATHER J AND MITCHELSON J. 1994. Cholinergic innervation and function in the prostate. *Pharmacol Ther* 94: 93–112.
- VICENTIC A, ROBEVA A, ROGGE G, UBERTI MA AND MINNEMAN KP. 2002. Biochemistry and pharmacology of epitope-tagged  $\alpha_1$ -adrenergic receptor subtypes. *J Pharmacol Exp Ther* 302: 58–65.
- VIVAS NM, GIRALDO J, TABERNERO A, VILA





- spontaneously hypertensive rat. *Naunyn Schmiedeberg's Arch Pharmacol* 356: 383–391.
- WALDEN PD, GERARDI C AND LEPOR H. 1999. Localization and expression of the  $\alpha_{1A-1}$ ,  $\alpha_{1B}$  and  $\alpha_{1D}$ -adrenoceptors in hyperplastic and non-hyperplastic human prostate. *J Urol* 161: 635–640.
- WALKER WH AND CHENG J. 2005. FSH and testosterone signalling in Sertoli cells. *Reproduction* 130: 15–28.
- WANG JM, MCKENNA KE AND LEE C. 1991. Determination of prostatic secretion in rats: effect of neurotransmitters and testosterone. *Prostate* 18: 289–301.
- WANG X ET AL. 2005. Spinophilin regulates  $Ca^{2+}$  signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. *Nat Cell Biol* 7: 405–411.
- WAUGH DJ, ZHAO MM, ZUSCIK MJ AND PEREZ DM. 2000. Novel aromatic residues in transmembrane domains IV and V involved in agonist binding at alpha(1a)-adrenergic receptors. *J Biol Chem* 275: 11698–11705.
- WESS J. 2004. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. *Annu Rev Pharmacol Toxicol* 44: 423–450.
- WIER WG AND MORGAN KG. 2003. Alpha1-adrenergic signalling mechanisms in contraction of resistance arteries. *Rev Phys Biochem Pharmacol* 150: 91–139.
- XIAO L AND JEFFRIES WB. 1998. Kinetics of alkylation of cloned rat alpha1-adrenoceptor subtypes by chloroethylclonidine. *Eur J Pharmacol* 347: 319–327.
- XU Z, HIRASAWA A, SHINOUE H AND TSUJIMOTO G. 1999. Interaction of the alpha(1B)-adrenergic receptor with gC1q-R, a multifunctional protein. *J Biol Chem* 274: 21149–21154.
- YAN HH, MRUK DD, LEE WM AND CHENG CY. 2007. Ectoplasmic specialization: a friend or a foe of spermatogenesis? *Bioessays* 29: 36–48.
- YANG M, VERFÜRTH F, BÜSCHER R AND MICHEL MC. 1997. Is alpha1D-adrenoceptor protein detectable in rat tissues? *Naunyn Schmiedeberg's Arch Pharmacol* 355: 438–446.
- YANG-FENG TL, XUE FY, ZHONG WW, COTECCHIA S, FRIELLE T, CARON MG, LEFKOWITZ RJ AND FRANKCE U. 1990. Chromosomal organization of adrenergic receptor genes. *Proc Natl Acad Sci USA* 87: 1516–1520.
- YANG-FENG TL, HAN H, LOMASNEY JW AND CARON MG. 1994. Localization of the cDNA for an alpha 1-adrenergic receptor subtype (ADRA1D) to chromosome band 20p13. *Cytogenet Cell Genet* 66: 170–171.
- YASUOKA A, ABE K, ARAI S AND EMORI Y. 1996. Molecular cloning and functional expression of the alpha1A-adrenoceptor of Medaka fish, *Oryzias latipes*. *Eur J Biochem* 235: 501–507.
- YAZAWA H AND HONDA K. 1993. Alpha 1-adrenoceptor subtype in the rat prostate is preferentially the alpha 1A type. *Jpn J Pharmacol* 62: 297–304.
- YAZAWA H, SAITA Y, IIDA E, HONMA Y, MORITA T AND HONDA K. 1994. Characterization of muscarinic cholinergic receptor in primary culture of smooth muscle cells from human prostate. *J Urol* 152: 2173–2177.
- YKI-JARVINEN H, WAHLSTROM T AND SEPPALA M. 1983. Immunohistochemical demonstration of relaxin in the genital tract of men. *J Reprod Fertil* 69: 693–695.
- YOSHINAGA T, ZHANG S, NIIDOME T, HIRAOKA M AND HIRANA Y. 1999. Potentiation of recombinant L-type Ca channel currents by alpha1-adrenoceptors coexpressed in baby hamster kidney (BHK) cells. *Life Sci* 64: 1643–1651.
- ZHAO L, ROCHE PJ, GUNNERSEN JM, HAMMOND VE, TREGGAR GW, WINTOUR EM AND BECK F. 1999. Mice without a functional relaxin gene are unable to deliver milk to their pups. *Endocrinology* 140: 445–453.
- ZHONG H AND MINNEMAN K. 1999. alpha 1 adrenoceptor subtypes. *Eur J Pharmacol* 375: 261–276.
- ZHONG H, LEE D, ROBEVA A AND MINNEMAN KP. 2001. Signalling pathways activated by alpha1-adrenergic receptor subtypes in PC12 cells. *Life Sci* 68: 2269–2276.
- ZIMMERMANN S, STEDING G, EMMEN JM, BRINKMANN AO, NAYERNIA K, HOSTEIN AF, ENGEL W AND ADHAM IM. 1999. Targeted disruption of the INsl3 gene causes bilateral cryptorchidism. *Mol Endocrinol* 13: 681–691.
- ZUSCIK MJ, PIASCIK MT AND PEREZ DM. 1999. Cloning, cell-type specificity, and regulatory function of the mouse alpha(1B)-adrenergic receptor promoter. *Mol Pharmacol* 56: 1288–1297.